NZ529903A - Novel substituted 1,3-propadiamides as cathepsin inhibitors - Google Patents

Novel substituted 1,3-propadiamides as cathepsin inhibitors

Info

Publication number
NZ529903A
NZ529903A NZ529903A NZ52990302A NZ529903A NZ 529903 A NZ529903 A NZ 529903A NZ 529903 A NZ529903 A NZ 529903A NZ 52990302 A NZ52990302 A NZ 52990302A NZ 529903 A NZ529903 A NZ 529903A
Authority
NZ
New Zealand
Prior art keywords
compound
alkyl
cyclohexylmethyl
cyanomethyl
malonamide
Prior art date
Application number
NZ529903A
Inventor
John W Patterson
Sheila Zipfel
Original Assignee
Axys Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharm Inc filed Critical Axys Pharm Inc
Publication of NZ529903A publication Critical patent/NZ529903A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/25—Aminoacetonitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Described is a compound of formula I as well as the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds. X1 is -NHC(R1)(R2)X2; X2 is cyano,-C(R7)R8X3; R6 is hydrogen or (C1-6) alkyl; R7 and R8 together form oxo; X3 comprises a heteromonocyclic ring containing 4 to 6 ring member atoms or a fused heterobicyclic ring system containing 8 to 14 ring member atoms and any carbocyclic ketone, iminoketone or thioketone derivative thereof; X4 is a bond or (C1-6)alkyl; R12 at each occurrence independently is hydrogen, (C1-6) alkyl and R14 is (C 3-10) cycloalkyl (C0-6)alkyl, hetero(C3-10)cycloalkyl(C0-3)alkyl, (C6-10) aryl(C0-6)alkyl, hetero(C5-10)aryl(C0-6)alkyl, (C9-10)bicycloaryl(C0-6)alkyl or hetero(C8-10) bicycloaryl(C0-6)alkyl; R1 is hydrogen; and R2 is hydrogen; R3 is -C(R6)(R6)X5, wherein R6 is as defined above and X5 is selected from -X4R12, -R14, -X4SR14, -X4S(O)2R14 wherein X4 R12 and R14 are as defined above; R4 is -NR6R6, -NR6R14, -NR6R15 or -NR6X5C(O)R14 wherein R6, X5 and R14 are as described above and R15 is hydrogen, -(C1-6) alkyl; wherein within R3 and R4 any alicyclic or aromatic ring system may be substituted further by nitro, -X4OR12, -X4C(O)NR12R12, -X4OR14, and within R3 and R4 any aliphatic moiety may be substituted further by cyano. The compound is described to be used in a pharmaceutical composition to inhibit Cathepsin S, for the treatment of diseases such as arthritis, muscular dystrophy, inflammation, malaria and periodontal disease.

Description

<div class="application article clearfix" id="description"> <p class="printTableText" lang="en">New Zealand Paient Spedficaiion for Paient Number 529903 <br><br> WO 02/098406 <br><br> 5299 <br><br> PCT/US02/17922 <br><br> NOVEL SUBSTITUTED 1,3-PROPADIAMIDES AS CATHEPSIN INHIBITORS <br><br> 10 <br><br> The Invention <br><br> This Application relates to compounds and compositions for treating diseases associated with cysteine protease activity, particularly diseases associated with activity of cathepsin S. <br><br> Description of the Field <br><br> Cysteine proteases represent a class of peptidases characterized by the presence of a cysteine residue in the catalytic site of the enzyme. Cysteine proteases are associated with the normal degradation and processing of proteins. The aberrant activity of cysteine proteases, e.g., as a result of increase expression or enhanced activation, however, may 15 have pathological consequences. In this regard, certain cysteine proteases are associated with a number of disease states, including arthritis, muscular dystrophy, inflammation, tumor invasion, glomerulonephritis, malaria, periodontal disease, metachromatic leukodystrophy and others. . An increase in cathepsin S activity contributes to the pathology and/or symptomatology of a number of diseases. Accordingly, molecules that 20 ■ inhibit the activity of cathepsin S protease are useful as therapeutic agents in the treatment of such diseases. <br><br> 1 <br><br> intellectual property office of n.z <br><br> 16 JUN 2005 RECEIVED <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> Summary of the Invention <br><br> The present invention relates to novel compounds of formula I: <br><br> r" <br><br> r <br><br> O <br><br> x <br><br> O <br><br> I <br><br> in which: <br><br> X1 is -NHC(R1)(R2)X2; <br><br> X is cyano, -C(R7)(R8)X3; R6 is hydrogen or (Cj-6) alkyl; R7 and R8 together form <br><br> X3 comprises a heteromonocyclic ring containing 4 to 6 ring member atoms or a fused heterobicyclic ring system containing 8 to 14 ring member atoms and any carbocyclic ketone, iminoketone or thioketone derivative thereof; <br><br> X4 is a bond or (Ci-6)alkyl; R12 at each occurrence independently is hydrogen, <br><br> (Ci-6)alkyl and R14 is (C3_io)cycloalkyl(Co-6)alkyl, <br><br> hetero(C3.10)cycloalkyl(C0_3)alkyl, (C6.i0)aryl(C0.6)alkyl, hetero(C5.,o)aryl(C0.6)alkyl, (C9.i0)bicycloaryl(C0.6)alkyl or hetero(C8.,0)bicycloaryl(C0.6)alkyl; <br><br> Rl is hydrogen; and R2 is hydrogen, <br><br> R3 is -C(R6)(R6)X5, wherein R6 is as defined above and X5 is selected from -X4R12, -R14, -X4SR14, -X4S(0)2R14, wherein X4, R12 and R14 are as defined above; <br><br> R4 is -NR6R6, -NR6R14, -NR6R15 or -NR6X5C(0)R14 wherein R6, X5 and R14 are as described above and R15 is hydrogen, -(Ci-6)alkyl; <br><br> wherein within R3 and R4 any alicyclic or aromatic ring system may be substituted further by nitro, -X4OR12, -X4C(0)NR12R12, -X4OR14, and within R3 and R4 any aliphatic moiety may be substituted further by cyano; and the TV-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof. <br><br> oxo; <br><br> 2 <br><br> intellectual property office of n.z. <br><br> 2 5 JUL 2005 <br><br> RECEItfEP <br><br> Also described are compounds of Formula I: <br><br> in which: <br><br> X1 is -NHC(R')(R2)X2 or -NHX3; <br><br> X2 is cyano, -C(R7)(R8)X3, -C(R7)(R8)CF3, -C(R7)(R8)CF2CF2R9 -CH=CHS(0)2R5, -C(0)CF2C(0)NR5Rs, -C(0)C(0)NR5R6, -C(0)C(0)0R5, -C(0)CH2OR5, -C(0)CH2N(R6)S02Rs or -C(0)C(0)R5; wherein R5 is (Cw)alkyl, (Cs.10)aiyl(C0.6)alkyl or (Cj^o^eteroarylCC^alkyl; R6 is hydrogen or (C,_6)alkyl; R7 is hydrogen or (CM)alkyl and R8 is hydroxy or R7 and R8 together form oxo; R9 is hydrogen, halo, (C^)alkyl, (CS-io)aryl(C(W)alkyl or (C5.,0)heteroaryl(C0.6)alkyl; <br><br> X3 comprises a heteromonocyclic ring containing 4 to 6 ring member atoms or a fused heterobicyclic ring system containing 8 to 14 ring member atoms and any carbocyclic ketone, iminoketone or thioketone derivative thereof; <br><br> wherein within R5, X2 or X3 any alicyclic or aromatic ring system may be substituted further by 1 to 5 radicals independently selected from (C,.6)alkyl, (C,.s)alkylidene, cyano, halo, halo-substituted(CM)alkyl, nitro, -X4NR12R12, -X4NR12C(0)R12, -X4NR12C(0)0R12, -X4NR12C(0)1SIR,2R12, -X4NR12C(NR12)NR12R12, -X4OR12, -X4SR12, -X4C(0)0R12, -X4C(0)R12, -X40C(0)R12, -X4C(0)NR12R12, -X4S(0)2NR12R12, -X4NR12S(0)2R12, -X4P(0)(0R12)0R12, -X40P(0)(0R12)0Riz, -X4NR12C(0)R13, -X4S(0)R13 and -X4S(0)2R13 and/or 1 radical selected from -R14, -X4OR14, -X4SR14, -X4S(0)R14, -X4S(0)2R14, -X4C(0)R14, -X4C(0)0R14, -X40C(0)R14, -X4NR14R12, -X4HR12C(0)R14, -X4NR12C(0)0R14, -X4C(0)NR12R12, -X4S(0)2NR14R12, -X4NR12S(0)2R14, -X4NR12C(0)NR14R12 and -X4NR12C(NR12)NRl4R12, wherein X4 is a bond or (C,.6)allcyl; R12 at each occurrence independently is hydrogen, (Cw)allcyl or halo-substituted(Cw)alkyl; R13 is (C^^alkyl or halo-substituted(C5,6)alkyl; and R14 is (C3_10)cycloalkyl(C0.6)alkyl, <br><br> 2a <br><br> 406641J.DOC <br><br> intellectual property office of n.z <br><br> 1 6 JUN 2005 RECEIVED <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> hetero(C3.1o)cycloalkyl(C0.3)alkyI, (C^ary^Q^alkyl, hetero(Cs.10)aryl(C0.s)alkyl, (C9.i0)bicycloaryl(Co.6)alkyl or hetero(C8.10)bicycloaryl(Co.6)alkyl; <br><br> R1 is hydrogen, halo or (C,.6)alkyl and R2 is selected from a group consisting of hydrogen, cyano, halo, -X4NR!2R12, -X4NR,2C(0)R12, -X4NR12C(0)0R12, 5 -X4NR12C(0)NR12R12, -X4NR12C(NR12)NR12R12, -X4OR12, -X4SR12, -X4C(0)0R12, -X4C(0)R12, -X40C(0)R12, -X4C(0)NR12R12, -X4S(0)2NR12R12, -X4NR!2S(0)2R'2, -X4P(0)(0R12)0R12, -X40P(0)(0R12)0R12, -X4NR,2C(0)R13, -X4S(0)R13, -X4S(0)2R13, -R14, -X4OR14, -X4SR14,-X4S(0)R14, -X4S(0)2R14, -X4C(0)R14, -X4C(0)0R14, -X40C(0)R14, -X4NR14R1?, -X4NR12C(0)R14, -X4NR'2C(0)0R14, -X4C(0)NR12R12, -X4S(0)2NR14R12, 10 -X4NR12S(0)2R14, -X4NR12C(0)NR14R12 and OC4NR12C(NR12)NR14R12, wherein X4, R12, R13 and R14 are as defined above; or R1 and R2 taken together with the carbon atom to which both R1 and R2 are attached form (C3„8)cycloaIkylene or (C3.8)heterocycloalkylene; wherein within said R2 any heteroaryl, aryl, cycloalkyl, heterocycloalkyl, cycloalkylene or heterocycloalkylene is optionally substituted with 1 to 3 radicals independently selected 15 from (C,.6)alkyl, (C^)alkylidene, cyano, halo, halo-substituted(CM)alkyl, nitro, -X4NR12R12, -X4NR12C(0)R12, -X4NR12C(0)0R12, -X4NR12C(0)NR12R12, -X4NR12C(NRI2)NR12R12, -X4OR12, -X4SR12, -X4C(0)0R12, -X4C(0)R12, -X40C(0)R12, -X4C(0)NR12R12, -X4S(0)2NR12R12, -X4NR12S(0)2R12, -X4P(0)(0R12)0R12, -X40P(0)(0R,2)0R12, -X4NR12C(0)R13, -X4S(0)R13, -X4S(0)2R13 and -X4C(0)R13, wherein 20 X4, R12 and R13 are as defined above; <br><br> R3 is -C(R6)(R6)X5, wherein R6 is as defined above and Xs is selected from -X4NR12R12, -X4NRI2C(0)R12, -X4NR12C(0)0Ri2, -X4NR'2C(0)NR12R12, -X4NR12C(NR12)NR12R12, -X4OR12, -X4SR12, -X4C(0)0R12, -X4C(0)R12, -X40C(0)R12, -X4C(0)NR12R12, -X4S(0)2NRI2R12, -X4NR12S(0)2R12, ~X4P(0)(0R12)0R12, -X4R12, 25 -X40P(0)(0R12)0R12, -X4C(0)R13, -X4NR12C(0)R13, -X4S(0)R13 and -X4S(0)2R13, -R14, -X4OR14, -X4SR14, -X4S(0)R34, -X4S(0)2R14, -X4C(0)R14, -X4C(0)0R14, -X40C(0)R14, -X4NR14R12, -X4NR12C(0)R14, -X4NR12C(0)0R14, -X4C(0)NR14R12, -X4S(0)2NR14R12, -X4NR12S(0)2R14, -X4NR12C(0)NR14R12 and -XW'CCNR^NR^R12 wherein X4, R12, R13 and R14 are as defined above; <br><br> 30 R4 is -NR®R6, -NRfiR14, -NR6R15 or -NR6X5C(0)R14 wherein R6, X5 and R14 are as described above and R15 is hydrogen, -(C,.6)aJkyl or -X5OR6 wherein Xs is as described <br><br> 3 <br><br> WO 02/098406 PCT/US02/17922 <br><br> above; or R6 and R15 together with the nitrogen atom to which R6 and R,s are attached form hetero(C3„I0)cycloalkyl, hetero(C5.10)aiyl or hetero(C8.10)bicycloaryl; <br><br> wherein within R3 and R4 any alicyclic or aromatic ring system may be substituted further by 1-5 radicals independently selected from (C,„6)alkyl, (C^alkylidene, cyano, 5 halo, halo-substituted(CM)alkyl, nitro, -X4NR12R12, -X4NR,2C(0)R12, -X4NR12C(0)0R12, -X4NR12C(0)NR12R12, -X4NR12C(NR12)NR12R12, -X4OR12, -X4SR12, -X4C(0)0R12, -X4C(0)R12, -X40C(0)R12, -X4C(0)NR'2R12, -X4S(0)2NRI2R12, -X4NR12S(0)2R12, -X4P(0)(0R12)0R12, -X40P(0)(0R,2)0R12, -X4NR12C(0)R13, -X4S(0)R13, -X4C(0)R13 and -X4S(0)2R13 and/or 1 radical selected from -R14, -X4OR'4, -X4SR14, -X4S(0)R14, 10 -X4S(0)2R14, -X4C(0)R14, -X4C(0)0R14, -X40C(0)R14, -X4NR14R12, -X4NRI2C(0)R'4, -X4NRI2C(0)0R14, -X4C(0)NR14R12, -X4S(0)2NR'4R12, -X4NR12S(0)2Ri4, -X4NRl2C(0)NR14R12 and -X4NR,2C(NR12)NR14R12; and within R3 and R4 any aliphatic moiety may be substituted further by 1-5 radicals independently selected from cyano, halo, nitro, -NR12R12, -NRl2C(0)R12, -NR12C(0)0R12, -NR12C(0)NR12R12, -NR12C(NR12)NR,2R12, 15 -OR12, -SR12, -C(0)0R12, -C(0)R12, -0C(0)R12, -C(0)NR,2R12, -S(0)2NR12R12, -NR12S(0)2R12, -P(0)(0R12)0R12, -0P(0)(0R12)0R12, -NR12C(0)R13, -S(0)R13 and -S(0)2R13; wherein X4, R12, R13 and R14 are as described above; <br><br> with the proviso that only one bicyclic ring structure is present within R3 or R4; and the TV-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and 20 mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof. <br><br> A second aspect of the invention is a pharmaceutical composition which contains a compound of Formula I or a AT-oxide derivative, individual isomer or mixture of isomers 25 thereof, or a pharmaceutically acceptable salt thereof, in admixture with one or more suitable excipients. <br><br> Also described is a method for treating a disease in an animal in which inhibition of cathepsin S can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease, which method comprises administering to the animal a 30 therapeutically effective amount of compound of Formula I or a TV-oxide derivative, individual isomer or mixture of isomers thereof; or a pharmaceutically acceptable salt intellectual property office <br><br> of n.z <br><br> 1 6 JUN 2005 <br><br> RECEIVER <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> thereof. <br><br> A fourth aspect of the invention is the processes for preparing compounds of Formula I and the TV-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable 5 salts thereof. <br><br> Detailed Description of the Invention <br><br> Definitions: <br><br> 10 Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this Application and have the following meanings. <br><br> "Alicyclic" means a moiety characterized by arrangement of the carbon atoms in closed non-aromatic ring structures having properties resembling those of aliphatics and 15 may be saturated or partially unsaturated with two or more double or triple bonds. <br><br> "Aliphatic" means a moiety characterized by a straight or branched chain arrangement of the constituent carbon atoms and may be saturated or partially unsaturated with two or more double or triple bonds. <br><br> "Alkyl" represented by itself means a straight or branched, saturated or unsaturated, 20 aliphatic radical having the number of carbon atoms indicated (e.g., (C^alkyl includes methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, terf-butyl, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, ethynyl, 1-propynyl, 2-propynyl, and the like). Alkyl represented along with another radical (e.g., as in arylalkyl) means a straight or branched, saturated or unsaturated aliphatic divalent 25 radical having the number of atoms indicated or when no atoms are indicated means a bond (e.g., (C6.10)aryl(Co_3)alkyl includes phenyl, benzyl, phenethyl, 1-phenylethyl 3-phenylpropyl, and the like). <br><br> "Alkylene", unless indicated otherwise, means a straight or branched, saturated or unsaturated, aliphatic, divalent radical having the number of carbon atoms indicated (e.g., 30 (C,.6)alkylene includes methylene (-CH2-), ethylene (-CH2CH2-), trimethylene (-CH2CH2CH2-), tetramethylene (-CH2CH2CH2CH2-) 2-butenylene (-CH2CH=CHCH2-), <br><br> 5 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> 2-methyltetramethylene (-CH2CH(CH3)CH2CH2-), pentamethylene <br><br> (-CH2CH2CH2CH2CH2~) and the like). <br><br> "Alkylidene" means a straight or branched saturated or unsaturated, aliphatic, divalent radical having the number of carbon atoms indicated (e.g. (Cj.6)alkylidene 5 includes methylidene (=CH2), ethylidene (=CHCH3), isopropylidene (=C(CH3)2), propylidene (=CHCH2CH3), allylidene (=CH"CH=CH2), and the like). <br><br> "Amino" means the radical -NH2. Unless indicated otherwise, the compounds of the invention containing amino moieties include protected derivatives thereof. Suitable protecting groups for amino moieties include acetyl, fert-butoxycaibonyl, 10 benzyloxycarbonyl, and the like. <br><br> "Animal" includes humans, non-human mammals (e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds, and the like). <br><br> "Aromatic" means a moiety wherein the constituent atoms make up an unsaturated ring system, all atoms in the ring system are sp2 hybridized and the total number of pi 15 electrons is equal to 4n+2. <br><br> "Aryl" means a monocyclic or fused bicyclic ring assembly containing the total number of ring carbon atoms indicated, wherein each ring is comprised of 6 ring carbon atoms and is aromatic or when fused with a second ring forms an aromatic ring assembly. For example, optionally substituted (Cwo)aryl as used in this Application includes, but is 20 not limited to, biphenyl-2-yl, 2-bromophenyl, 2-bromocarbonylphenyl, 2-bromo-5-fluorophenyl, 4-tert-butylphenyl, 4-carbamoylphenyl, 4-carboxy-2-nitrophenyl, 2-chlorophenyl, 4-chlorophenyl, 3-chlorocarbonylphenyl, 4-chlorocarbonylphenyl, 2-chloro-4-fIuorophenyI, 2-chIoro-6-fluorophenyl, 4-chloro-2-nitrophenyI, 6-chloro-2-nitrophenyl, 2,6-dibromophenyl, 2,3-dichlorophenyl, 2,5-dichlorophenyl, 25 3,4-dichlorophenyl, 2-difluoromethoxyphenyl, 3,5-dimefhylphenyl, <br><br> 2-ethoxycarbonylphenyl, 2-fluorqphenyl, 2-iodophenyl, 4-isqprqpylphenyl, <br><br> 2-methoxyphenyl, 4-methoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 5-methyl-2-nitrophenyl, 4-methylsulfonylphenyl, naphth-2-yl, 2-nitrophenyl, <br><br> 3-nitrophenyl, 4-nitrophenyl, 2,3,4,5,6-pentafluorophenyl, phenyl, 30 2-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, <br><br> 2-trifludromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, <br><br> 6 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> 2-trifluoromethylsulfanylphenyl, 4-trifluoromethylsulfanylphenyl, and the like. Optionally substituted (C6.I0)aiyl as used in this Application includes 3-acetylphenyl, <br><br> 3-fer^butoxycarbonylaminomethylphenyl, biphenyl-4-yl, 3-hydroxyphenyl, <br><br> 4-hydroxyphenyl, 3-methoxyphenyl, naphth-2-yl, 3-phenoxyphenyl, phenyl, and the like. 5 "Bicycloaryl" means a bicyclic ring assembly containing the number of ring carbon atoms indicated, wherein the rings are linked by a single bond or fused and at least one of the rings comprising the assembly is aromatic, and any carbocyclic ketone, thioketone or iminoketone derivative thereof (e.g., (C9.10)bicycloaiyl includes cyclohexylphenyl, 1,2-dihydronaphthyl, 2,4-dioxo-l,2,3,4-tetrahydronaphthyl, indanyl, indenyl, 10 1,2,3,4-tetrahydronaphthyl, and the like). <br><br> "Carbamoyl" means the radical -C(0)NH2. Unless indicated otherwise, the compounds of the invention containing carbamoyl moieties include protected derivatives thereof. Suitable protecting groups for carbamoyl moieties include acetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the like and both the unprotected and 15 protected derivatives fall within the scope of the invention. <br><br> "Carbocyclic ketone derivative" means a derivative containing the moiety —C(0)—. <br><br> "Carboxy" means the radical -C(0)0H. Unless indicated otherwise, the compounds of the invention containing carboxy moieties include protected derivatives 20 thereof. Suitable protecting groups for carboxy moieties include benzyl, tert-butyl, and the like. <br><br> "Cycloalkyl" means a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing the number of ring carbon atoms indicated, and any carbocyclic ketone, thioketone or iminoketone derivative thereof (e.g., 25 (C3.10)cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,5-cyclohexadienyl, bicyclo[2.2.2]octyl, adamantan-l-yl, decahydronaphthyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl, 2-oxobicyclo[2.2.1]hept-l-yl, and the like). . <br><br> "Cycloalkylene" means a divalent saturated or partially unsaturated, monocyclic 30 ring or bridged polycyclic ring assembly containing the number of ring carbon atoms indicated, and any carbocyclic ketone, thioketone or iminoketone derivative thereof. For <br><br> 7 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> example, the instance wherein "R1 and R2 together with the carbon atom to which both Rl and R2 are attached form (C3.s)cycloalkylene" includes, but is not limited to, the following: <br><br> "Disease" specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition that may be caused by, or incident to, medical or veterinary therapy applied to that animal, i.e., the "side effects" of such therapy. <br><br> "Halo" means fluoro, chloro, bromo or iodo; <br><br> "Halo-substituted alkyl", as an isolated group or part of a larger group, means "alkyl" substituted by one or more "halo" atoms, as such terms are defined in this Application. Halo-substituted alkyl includes haloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl and the like (e.g. halo-substituted (Ci.3)alkyl includes chloromethyl, dichloromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, perfluoroethyl, 2,2,2-trifluoro-l,l-dichloroethyl, and the like). <br><br> "Heteroatom moiety" includes -N=, -NR-, -0-, -S- or -S(0)2-, wherein R is hydrogen, (C,^)alkyl or a protecting group. <br><br> "Heterocycloalkylene" means cycloalkylene, as defined in this Application, provided that one or more of the ring member carbon atoms indicated, is replaced by heteroatom moiety selected from -N=, -NR-, -0-, -S- or -S(0)2-, wherein R is hydrogen or (Cw)alkyl. For example, the instance wherein R1 and R2 together with the carbon atom to which both R1 and R2 are attached form hetero(C3.8)cycloalkyl" includes, but is not limited to, the following: <br><br> 8 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> in which R is hydrogen, (C^alkyl, or a protecting group. <br><br> "Heteroaiyl" means aryl, as defined in this Application, provided that one or more of the ring carbon atoms indicated are replaced by a heteroatom moiety selected from -N=, -NR-, -O- or -S-, wherein R is hydrogen, (C^alkyl, a protecting group or represents the 5 free valence which serves as the point of attachment to a zing nitrogen, and each ring is comprised of 5 or 6 ring atoms. For example, optionally substituted hetero(C5.,0)aryl as used in this Application includes, but is not limited to, 4-amino-2-hydroxypyrimidin-5-yl, benzothiazol-2-yl, lH-benzoimidazol-2-yl, 2-bromopyrid-5-yl, 5-bromopyrid-2-yl, 4-carbamoylthiazol-2-yl, 3-carboxypyrid-4-yl, 5-carboxy-2,6-dimethylpyrid-3-yl, <br><br> 10 3,5-dimethylisoxazol-4-yl, 5-ethoxy-2,6-dimethylpyrid-3-yl, 5-fluoro- <br><br> 6-hydroxypyrimidin-4-yl, fur-2-yl, fur-3-yl, 5-hydroxy-4,6-dimethylpyrid-3-yl, 8-hydroxy-5,7-dimethylquinolin-2-yl, 5-hydroxymethylisoxazol-3-yl, 3-hydroxy-6-methylpyrid-2-yl, <br><br> 3-hydtoxypyrid-2-yl, l#-imidazol-2-yl, l/f-imidazol-4-yI, lff-indol-3-yl, isothiazol-4-yl, isoxazol-4-yl, 2-methylfur-3-yl, 5-methylfur-2-yl, 1 -methyl- l#-imidazol-2-yl, 5-methyl- <br><br> 15 3i7-imidazol-4-yl, 5-methylisoxazol-3-yl, 5-methyl-2ff-pyrazol-3-yl, 3-methylpyrid-2-yl, <br><br> 4-methylpyrid-2-yl, 5-methylpyrid-2-yl, 6-methylpyrid-2-yl, 2-methylpyrid-3-yl, 2-methylthiazol-4-yl, 5-nitropyrid-2-yl, 2i?-pyrazol-3-yl, 3fl-pyrazol-4-yl, pyridazin-3-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 5-pyrid-3-yl-2H-[l,2,4]triazol-3-yl, pyrimidin-4-yl, pyrimidin-5-yl, lff-pyrrol-3-yl, quinolin-2-yl, l/f-tetrazol-5-yl, thiazol-2-yl, thiazol-5-yl, <br><br> 20 thien-2-yl, thien-3-yl, 2i7-[l,2,4]triazol-3-yl, 3fl"-[l,2,3]triazol-4-yl, <br><br> 5-trifluoromethylpyrid-2-yl, and the like. Suitable protecting groups include /er/-butoxycarbonyl, benzyloxycarbonyl, benzyl, 4-methoxyben2yl, 2-nitrobenzyl, and the like. Optionally substituted hetero(C5.10)aryl as used in this Application to define R4 includes benzofur-2-yl, fur-2-yl, fur-3-yl, pyrid-3-yl, pyrid-4-yl, quinol-2-yl, quinol-3-yl, <br><br> 25 thien-2-yl, thien-3-yl, and the like. • <br><br> "Heterobicycloaryl" means bicycloaryl, as defined in this Application, provided that one or more of the ring carbon atoms indicated are replaced by a heteroatom moiety selected from -N=, -NR-, -O- or -S-, wherein R is hydrogen, (C^alkyl, a protecting group or represents the free valence which serves as the point of attachment to a ring nitrogen, <br><br> 30 and any carbocyclic ketone, thioketone or iminoketone derivative thereof. For example, optionally substituted hetero(C8.10)bicycloaryl as used in this Application includes, but is <br><br> 9 <br><br> WO 02/098406 PCT/US02/17922 <br><br> not limited to, 2-amino-4-oxo-3,4-dihydropteridin-6-yl, and the like. In general, the term heterobicycloaryl as used in this Application includes, for example, benzo[l,3]dioxol-5-yl, 3,4-dihydro-2#-[ 1,8]naphthyridinyl, 3,4-dihydro-2H-quinolinyl, 2,4-dioxo-3,4-dihydro-2#-quinazolinyl, l,2,3,4,5,6-hexahydro[2,2']bipyridinylyl, 3-oxo- <br><br> 5 2,3-dihydrobenzo[l,4]oxazinyl, 5,6,7,8-tetrahydroquinolinyl, and the like. <br><br> "Heterocycloalkyr means cycloalkyl, as defined in this Application, provided that one or more of the ring carbon atoms indicated are replaced by a heteroatom moiety selected from -N=, -NR-, -0- or -S-, wherein R is hydrogen, (C^alkyl, a protecting group or represents the free valence which serves as the point of attachment to a ring nitrogen, 10 and any carbocyclic ketone, thioketone or iminoketone derivative thereof (e.g., the term hetero(C5_10)cycloalkyl includes imidazolidinyl, morpholinyl, piperazinyl, piperidyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, and the like). Suitable protecting groups include tot-butoxycarbonyl, benzyloxycarbonyl, benzyl, 4-methoxybenzyl, 2-nitrobenzyl, and the like. Both the unprotected and protected derivatives fall within the scope of the invention. 15 "Hydroxy" means the radical -OH. Unless indicated otherwise, the compounds of the invention containing hydroxy radicals include protected derivatives thereof. Suitable protecting groups for hydroxy moieties include benzyl and the like. <br><br> "Iminoketone derivative" means a derivative containing the moiety -C(NR)-, wherein R is hydrogen or (C^alkyl. <br><br> 20 "Isomers" mean compounds of Formula I having identical molecular formulae but differ in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers" and stereoisomers that are nonsuperimposable mirror images are termed 25 "enantiomers" or sometimes "optical isomers". A carbon atom bonded to four nonidentical substituents is tenned a "chiral center". A compound with one chiral center has two enantiomeric forms of opposite chirality is tenned a "racemic mixture". A compound that has more than one chiral center has 2""1 enantiomeric pairs, where n is the number of chiral centers. Compounds with more than one chiral center may exist as ether an individual 30 diastereomers or as a mixture of diastereomers, termed a "diastereomeric mixture". When one chiral center is present a stereoisomer may be characterized by the absolute <br><br> 10 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> configuration of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. Enantiomers are characterized by the absolute configuration of their chiral centers and described by the R- and ^-sequencing rules of Cahn, Ingold and Prelog. Conventions for stereochemical nomenclature, methods 5 for the determination of stereochemistry and the separation of stereoisomers are well ■ known in the art (e.g., see "Advanced Organic Chemistry", 4th edition, March, Jeny, John Wiley &amp; Sons, New York, 1992). It is understood that the names and illustration used in this Application to describe compounds of Formula I are meant to be encompassed all possible stereoisomers. Thus, for example, the name /V-[ 1 -(1 -Benzylcarbamoyl-10 methanoyl)-propyl]-4-morpholin-4-yl-4-oxo-2-phenylmethanesulfonyhnethyl-butyramide is meant to include 7V-[(S)-1 -(1 -Benzylcarbamoyl-methanoyl)-propyl]-4-morpholin-4-yl-4-oxo-2-phenylmethanesulfonylmethyl-butyramide and jV-[(R)-l-(l-Benzylcarbamoyl-methanoyl)-propyl]-4-morpholin-4-yl-4-oxo-2-phen.ylmethanesulfonylmethyl-butyramide and any mixture, racemic or otherwise, thereof. <br><br> 15 "Ketone derivative" means a derivative containing the moiety -C(0)-. For example, in this Application X3 can be 2-acetoxy-azetidin-3-yl. The "carbocyclic ketone derivative" of this example of X3 would be 2-acetoxy-4-oxo-azetidin-3-yl (see Table 3, C32). <br><br> "Nitro" means the radical -N02. <br><br> 20 "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, the phrase "wherein within R3 and R4 any alicyclic or aromatic ring system may be substituted further by 1-5 radicals..." means that R3 and R4 may or may not be substituted in order to fall 25 within the scope of the invention. <br><br> "Oxoalkyl" means alkyl, as defined above, wherein one of the number of carbon atoms indicated is replaced by an oxygen group (-0-), e.g., oxo(C2^)alkyl includes methoxymethyl, etc. <br><br> 'W-oxide derivatives" means derivatives of compounds of Formula I in which 30 nitrogens are in an oxidized state (i.e., O-N) and which possess the desired pharmacological activity. <br><br> 11 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> "Pathology" of a disease means the essential nature, causes and development of the disease as well as the structural and functional changes that result from the disease processes. <br><br> "Pharmaceutically acceptable" means that which is useful in preparing a 5 pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use. <br><br> "Pharmaceutically acceptable salts" means salts of compounds of Formula I which are pharmaceutically acceptable, as defined above, and which possess the desired 10 pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartatic acid, citric acid, 15 benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, madelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, _p-toluenesulfonic acid, camphorsulfbnic acid, 4-methylbicyclo[2.2.2]oct-2-ene-l-carboxylic acid, glucoheptonic acid, 20 4,4'-methylenebis(3-hydroxy-2-ene-l-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like. <br><br> Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic 25 bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, iV-methylglucamine and the like. <br><br> "Prodrug" means a compound which is convertible in vivo by metabolic means 30 (e.g. by hydrolysis) to a compound of Formula I. For example an ester of a compound of Formula I containing a hydroxy group may be convertible by hydrolysis in vivo to the <br><br> 12 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> parent molecule. Alternatively an ester of a compound of Formula I containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule. Suitable esters of compounds of Formula I containing a hydroxy group, are for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, 5 maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-j?-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, <br><br> p-toluenesulphonates, cyclohexylsulphamates and quinates. Suitable esters of compounds <br><br> * <br><br> of Formula I containing a carboxy group, are for example those described by F.J.Leinweber, Drug Metab. Res., 1987,18, page 379. An especially useful class of esters 10 of compounds of Formula I containing a hydroxy group, may be formed from acid moieties selected from those described by Bundgaard et al, J. Med. Chem., 1989, 32, page 2503-2507, and include substituted (aminomethyl)-benzoates, for example, dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or interrupted by an oxygen atom or by an optionally substituted nitrogen atom, e.g. an alkylated nitrogen 15 atom, more especially (morpholino-methyl)benzoates, e.g. 3-. or 4-(moipholinomethyl)-benzoates, and (4-alkyIpiperazin-l-yl)benzoates, e.g. 3- or 4-(4-alkylpiperazin-1 -yl)-benzoates. <br><br> "Protected derivatives" means derivatives of compounds of Formula I in which a reactive site or sites are blocked with protecting groups. Protected derivatives of 20 compounds of Formula I are useful in the preparation of compounds of Formula I or in themselves may be active cathepsin S inhibitors. A comprehensive list of suitable protecting groups can be found in T.W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley &amp; Sons, Inc. 1999. <br><br> "Therapeutically effective amount" means that amount which, when administered 25 to an animal for treating a disease, is sufficient to effect such treatment for the disease. <br><br> "Thioketone derivative" means a derivative containing the moiety -C(S)-. <br><br> "Treatment" or "treating" means any administration of a compound of the present invention and includes: <br><br> (1) preventing the disease from occurring in an animal which may be predisposed to 30 the disease but does not yet experience or display the pathology or symptomatology of the disease, <br><br> 13 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> (2) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., arresting further development of the pathology and/or symptomatology), or <br><br> (3) ameliorating the disease in an animal that is experiencing or displaying the 5 pathology or symptomatology of the diseased (i.e., reversing the pathology and/or symptomatology). <br><br> Nomenclature: <br><br> The compounds of Formula I and the intermediates and starting materials used in 10 their preparation are named in accordance with IUPAC rules of nomenclature in which the characteristic groups have decreasing priority for citation as the principle group as follows: acids, esters, amides, etc. Alternatively, the compounds are named by AutoNom 4.0 (Beilstein Information Systems, Inc.). For example, a compound of Formula I in which X1 is -NHC^^CR^X2 (R1 and R2 are each hydrogen), X2 is cyano, R3 is cyclohexylmethyl, 15 and R4 is phenylamino; that is, a compound having the following structure: <br><br> i yN <br><br> is named iV-cvanomethvl-2-cvclohexvlmethvl-iV-phenvl-malonamide. <br><br> 20 Presently Preferred Embodiments: <br><br> "While the broadest definition of the invention is set forth in the Summary of the Invention, certain aspects of the invention are preferred. For example, X1 is -NHC(R')(R2)X2 or -NHX3; X2 is cyano, -C(0)X3, -C(0)CF3, -C(0)CF2CF2R9, -CH=CHS(0)2R5, -C(0)CF2C(0)NR5R5, -C(0)C(0)NR5R6, -C(0)C(0)0R5, -25 C(0)CE&gt;0R5, -C(0)CH2N(R6)S02R5 or -C(0)C(0)R5; wherein Rs and R6 are as described <br><br> 14 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> above; X3 comprises a heteromonocyclic ring containing 4 to 6 ring member atoms or a fused heterobicyclic ring system containing 8 to 14 ring member atoms and any carbocyclic ketone, iminoketone or thioketone derivative thereof; wherein within R5, X2 or X3 any alicyclic or aromatic ring system may be substituted further by 1 to 5 radicals 5 independently selected from (Cw)alkyl or -X40C(0)R12 and/or 1 radical selected from -R14, -X4C(0)R14 or -X40C(0)R14; wherein X4, R12 and R14 are as described above; R1 is hydrogen or (C1.5)alkyl and R2 is hydrogen, -X4OR12, (c5.10)heteroaryl(c0_6)alkyl, (C5.10)aryl(C0.6)alkyl, (C5.10)cycloalkyl(C0.6)alkyl, (C5.10)heterocycloalkyl(C0.6)alkyl or (C,.6)alkyl; or R1 and R2 taken together with the carbon atom to which both R1 and R2 are 10 attached form (C3.g)cycloalkylene or (C3.g)heterocycloalkylene; wherein within said R2 any heteroaryl, aryl, cycloalkyl, heterocycloalkyl, cycloalkylene or heterocycloalkylene is optionally substituted with 1 to 3 radicals independently selected from (C^alkyl and hydroxy; R3 is -CH2X5, wherein X5 at each occurrence independently is selected from -X4SR12, -X4C(0)NR12R12, -X4S(0)2R13, -X4C(0)R13, -X4SR14, -X4R12, -R14, -X4S(0)2R14, 15 -X4C(0)R14, -X4C(0)NR!4R12, wherein X4, R12, R13 and R14 are as defined above; R4 is -NR6R6, -NR6R14, -NR®R1S or -NR6XsC(0)R14 wherein R6, X5 and R14 are as described above and R15 is hydrogen, -(Ci.6)alkyl or -XsOR6 wherein X5 is as described above; or R6 and R15 together with the nitrogen atom to which R6 and R15 are attached form hetero(C3. 10)cycloalkyl, hetero(C5.10)aiyl or hetero(Cg.10)bicycloaryl; wherein within R3 and R4 any 20 alicyclic or aromatic ring system may be substituted further by 1 -5 radicals independently selected from (CM)alkyl, cyano, halo, nitro, halo-substituted(CM)alkyl, -X4OR12, -X4C(0)0R12, -X4C(0)R13, -X4C(0)NR12R12, -X4NRl2S(0)2R12 and/or 1 radical selected from -R14, -X4OR14 and -X4C(0)NR14R12; within R3 and R4 any aliphatic moiety may be substituted further by 1-5 radicals independently selected from cyano; wherein X4, R12, R13 25 and R14 are as described above; with the proviso that only one bicyclic ring structure is present within R3 or R4. <br><br> In particular, X1 is -NHC(R')(R2)X2 or -NHX3; X2 is cyano, -C(0)X3, -CF3, -CF2CF3, (E)-2-benzenesulfonyl-vinyl, 2-dimethylcarbamoyl-2,2-difluoro-acetyl, 1 -benzylcarbamoyl-methanoyl, l-benzyloxy(oxalyl), 2-benzyloxy-acetyl, 30 2-benzenesulfonylaxnino-ethanoyl or 2-oxo-2-phenyl-ethanoyl; X3 is liJ-benzoimidazol-2-yl, pyrimidin-2-yl, benzooxazol-2-yl, benzothiazol-2-yl, <br><br> 15 <br><br> WO 02/098406 PCT/US02/17922 <br><br> pyridazin-3-yl, 3-phenyl-[ 1,2,4]oxadiazol-5-yl, 3-ethyl-[ 1 ,2,4]oxadiazol-5-yl, <br><br> 2-methyl-4-oxo-tetrahydro-furan-3-yl, 2-ethyl-4-oxortetrahydro-furan-3-yl, 4-oxo-lr(l-phenyl-methanoyl)-pyrrolidin-3-yl or (S)-2-Acetoxy-4-oxo-azetidin-3-yl; R1 is hydrogen or methyl and R2 is hydrogen, methoxymethyl, (QJalkyl, phenethyl, <br><br> 5 thiophen-2-yl or 5-methyl-furan-2-yl, or (ii) R1 and R2 taken together with the carbon atom to which both R1 and R2 are attached form cyclopropylene, tetrahydro-pyran-4-ylene or methyl-piperidin-4-ylene. <br><br> R3 more preferably is thiophene-2-sulfonylmethyl, <br><br> 3-chloro-2-fluoro-phenylmethanesulfonylmethyl, benzenesulfonylmethyl, 10 phenylmethanesulfonylmethyl, 2-(l,l-difluoro-methoxy)-phenylmethanesulfony]methyl, <br><br> 2-benzenesulfonyl-ethyl, 2-(pyridine-2-sulfonyl)-ethyl, 2-(pyridine-4-sulfonyl)-ethyl, 2-phenylmethanesulfonyl-ethyl, oxy-pyiidin-2-ylmethanesulfonylmethyl, <br><br> prop-2-ene-l-sulfonylmethyl, 4-methoxy-phenyhnethanesulfonylmethyl, <br><br> /&gt;-tolylmethanesulfonylmethyl, 4-chloro-phenylmethanesulfonylmethyl, <br><br> 15 o-tolylmethanesulfonylmethyl, 3,5-dimethyl-phenylmethanesulfonylmethyl, <br><br> 4-trifluoromethyI-phenylmethanesuIfonylmethyI, 4-trifluoromethoxy-phenylmethanesulfonylmethyl, <br><br> 2-bromo-phenylmethanesulfonylmethyl, pyridin-2-ylmethanesulfonylmethyl, pyridin-3-ylmethanesulfonylmethyl, pyridin-4-ylmethanesulfonylmethyl, <br><br> 20 naphthalen-2-ylmethanesulfonylmethyl, 3-methyl-phenylmethanesulfonylmethyl, <br><br> 3-trifluoromethyl-phenylmethanesulfonylmethyl, <br><br> 3-trifluoromethoxy-phenylmethanesulfonylmethyl, <br><br> 4-fluoro-2-trifluoromethoxy-phenylmethanesulfonylmethyI, 2-fluoro-6-trifluoromethyl-phenylmethanesulfonylmethyl, <br><br> 25 3-chloro-phenylmethanesulfonylmethyl, 2-fluoro-phenylmethanesulfonylmethyl, 2-trifluoro-phenylmethanesulfonylmethyl, 2-cyano-phenylmethanesulfonylmethyl, 4-ter^-butyl-phenylmethanesulfonylmethyl, <br><br> 2-fluoro-3-methyl-phenylmethanesulfonylmethyl, 3-fluoro-phenylmethanesulfonylmethyl, 4-fluoro-phenylmethanesulfonylmethyl, 2-chloro-phenylmethanesulfonylmethyl, 30 2,5-difluoro-phenylmethanesulfonylmethyl, 2,6-difluoro-phenylmethanesulfonylmethyl, 2,5-dichloro-pheaylmethanesulfonylmethyl, 3,4-dichloro-phenylmethanesulfonylmethyl, <br><br> 16 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> 2-(l,l-difluoro-methoxy)-phenyhnethanesulfonylmethyl, <br><br> 2-cyano-phenylmethanesulfonylmethyl, 3-cyano-phenyhnethanesulfonylmethyl, <br><br> 2-trifluoromethoxy-phenylmethanesulfonylmethyl, <br><br> 2.3-difluoro-phenyhnethanesulfonyhnethyl,2,5-difluoro-phenybnethanesulfonylmethyl, 5 biphenyl-2-ylmethanesulfonylmethyl, cyclohexylmethyl, <br><br> 3-fluoro-phenylmethanesulfonyhnethyl, 3,4-difluoro-phenylmethanesulfonylmethyl, <br><br> 2.4-difluoro-phenylmethanesulfonylmethyl, 2,4,6-trifluoro-phenylmethanesulfonylmethyl, <br><br> 2.4.5-trifluoro-phenyhnethanesulfonylmethyl, 2,3,4-trifluoro-phenyImethanesulfonyImethyl, <br><br> 10 2,3,5-trifluoro-phenylmethanesulfonylmethyl, <br><br> 2.5.6-trifluoro-phenyhnethanesulfonylmethyl, <br><br> 2-chloro-5-trifluoromethylphenyhnethanesulfonylmethyl, 2-methyl-propane-l-sulfonyl, 2-fluoro-3-trifluoromethylphenylmethanesulfonylmethyl, 2-fluoro-4-trifluoromethylphen.ylmetbanesulfonylmeth.yl, 15 2-fluoro-5-trifhioromethylphenyhnethanesulfonylmethyl, <br><br> 4-fluoro-3-trifluoromethylphenylmethanesulfonylmethyl, <br><br> 2-methoxy-phenylmethanesulfonylmethyl, 3,5 bis-trifluoromethyl-phenylmethanesulfonylmethyl, <br><br> 4-difluon&gt;methoxy-phenylmethanesulfonylme£hyl, 20 2-difluoromethoxy-phenylmethanesulfonylmethyl, <br><br> 3-difluoromethoxy-phenylmethanesulfonylmethyl, <br><br> 2,6-dichloro-phenyImethanesulfonylmethyl, biphenyl-4-ylmethanesulfonylmethyl, <br><br> 3.5-dimethyl-isoxazol-4-ylmethanesulfonylmethyl, <br><br> 5-chloro-thiophen-2-ylmethanesulfonylmethyl, <br><br> 25 2-[4-(l,l-Difhioro-methoxy)-benzenesulfonyl]-ethyl, 2-[2-(l,l-Difluoro-methoxy)-benzenesulfonyl]-ethyl, 2-[3-(l,l-Difluoro-methoxy)-benzenesulfonyl]-ethyl, 2-(4-trifluoromethoxy-benzenesulfonyl)-ethyl, 2-(3-trifluoromethoxy-benzenesulfonyl)-ethyl, 30 2-(2-trifluoromethoxy-benzenesulfonyl)-ethyl, (cyanomethyl-methyl-carbamoyl)-methyl, butyl, biphenyl-3-ylmethyl, 2-oxo-2-pyrrolidin-l-yl-ethyl, 2-benzenesulfonyl-ethyl, <br><br> 17 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> isobutylsulfanylmethyl, 2-phenylsulfanyl-ethyl, cyclohexylmethanesulfonyhnethyl, 2-cyclohexyl-ethanesulfonyl, benzyl, naphthalen-2-yl, benzylsulfanylmethyl, <br><br> 2-trifluoromethyl-benzylsulfanylmelhyl, 5-bromo-thiophen-2-ylmethyl, phenylsulfanyl-ethyl and cyclopropylmethanesulfonylmethyl. <br><br> R4 more preferably is phenylamino, benzylamino, 4-phenoxy-phenylamino, phenethylamino, 3-phenyl-propylamino, morpholin-4-yl, cyclohexylamino, naphthalen-1-ylmethyl-amino, pyridin-3-yIamino, 6-methoxy-pyridin-3-ylamino, diisobutylamino, 4-nitro-benzylamino, 2-thiophen-2-yl-ethylamino, 3-phenoxy-phenylaxnino, cyanomethyl-amino, (pyridin-3-ylmethyl)-amino, 5,6,7,8-tetrahydro-naphthalea-l-ylamino, 2-pyridin-2-yl-ethylamino, 2,3-dihydro-indol-1 -yl, 3,4-dihydro-lH-isoquinolin-2-yl, <br><br> cyclohexylmethyl-amino, 2-methoxy-benzylamino, 1-phenyl-ethylamino, (pyridin-4-ylmethyl)-amino, benzyl-methyl-amino, 3-nitro-benzylamino, 4-methoxy-phenylamino, <br><br> 3-carbamoyl-phenylamino, 4-carbamoyl-phenylamino, (tetrahydro-fiiran-2-ylmethyl)-amino, 3,4-dihydro-2H-quinolin-l-yl, dimethylamino, butylmethylamino, diisopropylamino, propylmethylamino, l-(benzooxazole-2-carbonyl)-propylamino and isobutylmethylamino. <br><br> Reference to the preferred embodiments set forth above is meant to include all combinations of particular and preferred groups. <br><br> Particular compounds of the invention are selected from the compounds formed by joining the acyl carbon atom (C*) of one of the fragments (A1 to A37) shown in Table 1 to the methine carbon atom (*CH*) of one of the fragments (B1 to B88) shown in Table 2, and joining the methine carbon atom (*CH*) of one of the fragments (B1 to B88) shown in Table 2 to the acyl carbon atom (C*) of one of the fragments (CI to C36) depicted in Table 3. <br><br> The following tables are intended to provide guidance to better carry out the present invention. However, they do not limit the scope of the invention. People of ordinary skill may selectively make particular compounds by joining of one of the fragments shown in Table 1 to any one of the fragments shown in Table 2, and then joining the fragments shown in Table 2 to the any of one of the fragments Table 3. <br><br> 18 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> TABLE 1 <br><br> 19 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> A22 <br><br> OX <br><br> II <br><br> 0 <br><br> A23 <br><br> Oy.. <br><br> A24 <br><br> OUs. <br><br> ii <br><br> 0 <br><br> A25 <br><br> CU. <br><br> II <br><br> 0 <br><br> A26 <br><br> H <br><br> uu%. <br><br> II <br><br> 0 <br><br> A27 <br><br> A28 <br><br> A29 <br><br> fry <br><br> 0 <br><br> A30 <br><br> OvJk o c* <br><br> II <br><br> 0 <br><br> A31 <br><br> v c* <br><br> II <br><br> 0 <br><br> A32 <br><br> 1 <br><br> /■s. <br><br> II <br><br> 0 <br><br> A33 <br><br> 0 <br><br> A34 <br><br> 1 <br><br> r <br><br> 0 <br><br> A35 <br><br> \ 1 <br><br> i^r <br><br> 1 0 <br><br> A36 <br><br> r <br><br> Yt <br><br> 1 0 <br><br> A37 <br><br> TABLE2 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> B1 <br><br> 9 <br><br> o3s^ *CH* <br><br> B2 <br><br> &amp;: <br><br> o2s^ <br><br> *CH* <br><br> B3 <br><br> 9 <br><br> oas^ *CH* <br><br> B4 <br><br> G, <br><br> o2s^ *CH* <br><br> B5 <br><br> ^.OCHF, <br><br> o2s^ *CH* <br><br> B6 <br><br> J* <br><br> *CH* <br><br> B7 <br><br> on. <br><br> B8 <br><br> jQ <br><br> *CH* <br><br> B9 <br><br> 9 <br><br> *CH* <br><br> BIO <br><br> 0^ <br><br> o2s^ *CH* <br><br> Bll <br><br> "i o2s^ *CH* <br><br> B12 <br><br> o2s^ *CH* <br><br> B13 <br><br> "XX <br><br> o2s^ *CH* <br><br> B14 <br><br> "XX <br><br> o2s^ *CH* <br><br> B15 <br><br> O; <br><br> o2s^ *CH* <br><br> B16 <br><br> CH3 <br><br> aj^ <br><br> o2s^ *CH* <br><br> PB17 <br><br> '"XX, <br><br> o2s^ *CH* <br><br> B18 <br><br> o3s^ *CH* <br><br> \ <br><br> 21 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> 22 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> B37 <br><br> X5 <br><br> 02S^ P *CH* <br><br> B38 <br><br> A" <br><br> o2s^ *CH* <br><br> B39 <br><br> *CH* <br><br> B40 <br><br> 6, <br><br> o2s^ *CH* <br><br> B41 <br><br> KX <br><br> *CH* <br><br> B42 <br><br> op o2s^| *CH* <br><br> B43 <br><br> 6; <br><br> o2s^ *CH* <br><br> B44 <br><br> *CH* <br><br> B45 <br><br> *CH* <br><br> B46 <br><br> o2s^ *CH* <br><br> B47 <br><br> o2s^ *CH* <br><br> B48 <br><br> rxx; <br><br> o2s^ *CH* <br><br> B49 <br><br> P o2s^ <br><br> *CH* <br><br> B50 <br><br> 'A' <br><br> o2s^ *CH* <br><br> B51 <br><br> o2s^ *CH* <br><br> B52 <br><br> -A <br><br> o2s^ *CH* <br><br> B53 <br><br> oas^ *CH* <br><br> B54 <br><br> A' <br><br> P o2s^ <br><br> *CH* <br><br> 23 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> 24 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> TABLE 3 <br><br> CI <br><br> 1 <br><br> 0 <br><br> C2 <br><br> 1 t <br><br> 0 ^0 <br><br> 1 <br><br> C3 <br><br> IT <br><br> 8 <br><br> -fx <br><br> 0 <br><br> 25 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> c4 <br><br> 's0 <br><br> c5 <br><br> h ^ <br><br> 1 <br><br> ch3 <br><br> c6 <br><br> h K h i yx^} <br><br> c7 <br><br> .c^-sAcp, <br><br> ii i 3 <br><br> 0 / <br><br> c8 <br><br> 0 <br><br> h <br><br> * II i c9 <br><br> i YY J <br><br> cio <br><br> *s Y <br><br> 0 V / <br><br> cll <br><br> JLy^ <br><br> *fi Y <br><br> ° Q <br><br> c12 <br><br> ^sAf°V^ 1 j Lq, <br><br> c13 <br><br> r/% <br><br> c14 <br><br> h V° <br><br> •fir^O <br><br> 6 <br><br> c15 <br><br> c16 <br><br> c17 <br><br> h jj h 0^0 <br><br> c18 <br><br> y".XSCH&gt; <br><br> c19 <br><br> 0 y? X—¥ <br><br> b c20 <br><br> o yS N—y c21 <br><br> h § h hi 0 0 <br><br> c22 <br><br> ■MP <br><br> 0 y) 0 <br><br> c23 <br><br> . jsjyovjo <br><br> 0 yS 0. <br><br> c24 <br><br> h 1 <br><br> nrvk-f' <br><br> j1 = <br><br> ° / <br><br> c25 <br><br> H H It <br><br> *c Y X N <br><br> 0 ^ r » » <br><br> c26 <br><br> tM <br><br> c27 <br><br> 1^5 <br><br> 26 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> C28 <br><br> 0 ^ <br><br> C29 <br><br> « A <br><br> C30 <br><br> " I o* % 0 ^ <br><br> C31 <br><br> TM <br><br> C32 <br><br> H /? <br><br> ■rd <br><br> C33 <br><br> .JKK <br><br> 0 J <br><br> X) <br><br> / <br><br> y=° <br><br> 0 <br><br> C34 <br><br> . r <br><br> 0 J : <br><br> C35 <br><br> 0 <br><br> r^ii <br><br> C36 <br><br> Y Yj <br><br> 0 / ' <br><br> U <br><br> Thus, for example, in table 4 the compound denoted as A2-B45-C35 is the product of the combination of group A2 in Table 1 and B45 in Table 2 and C35 in Table 3, namely jV-f 1-f 1 -benzooxazol-2-vl-methanovlV 3 -phenyl-propyl] -iV-benzvl-2-cvclohexvlmethvl-malonamide: <br><br> Further preferred are compounds of Formula I selected from a group consisting of: 2-butvl-iV-cvanomethvl-jV-phenvl-malonamide (Compound 1; denoted as Al-B88-C1); <br><br> jV-Cvanomethvl-2-cvclohexvlmethvl-iV-phenvl-malonamide (Compound 2; denoted as A1-B45-C1); <br><br> JV-Cvanomethvl-2-cvclohexvlmethvl-JV-phenethyl-malonamide (Compound 3; denoted as A4-B45-C1); <br><br> 27 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> iV-Cvanomethvl-2-cvclohexvlmethvl-jV-pvridin-4-vlmethvl-malonamide (Compound 4; denoted as A24-B45-C1); <br><br> N-\ 1 -rBenzooxazole-2-carbonvlV3-phenvl-propvl1-7V-benzvl-2-cvclohexvlmethvl-malonamide (Compound 5; denoted as A2-B45-C35); <br><br> 5 iV-Cvanomethvl-jV-cvclohexvl-2-cvclohexvlmethvl-malonamide (Compound 6; <br><br> denoted as A7-B45-C1); <br><br> jV-Benzvl-jV-cvanomethvl-2-cvclohexvlmethvl-malonatnide (Compound 7; denotes as A2-B45-C1); <br><br> N-Cvanomethvl-2-cvclohexvlmethvl-7V-C4-phenoxv-nhenvlVmalonamide 10 (Compound 8; denoted as A3-B45-C1); <br><br> iy-Cvanomethvl-2-cvclohexvlmethvl-iV-f3-phenvl-propvlVmalonamide (Compound 9; denoted as A5-B45-C1); <br><br> jy-Cvanomethvl-2-cvclohexvlmethvl-3-morpholin-4-vl-3-oxo-propionamide (Compound 10; denoted as A6-B45-C1); 15 iV-Cvanomethvl-2-cvclohexvlmethvl-7V-naphtbalen-l-vlmethvl-malonamide <br><br> (Compound 11; denoted as A8-B45-C1); <br><br> iV-Cvanomethvl-2-cvclohexvlmethvl-iV-pvridin-3-vl-malonamide (Compound 12; denoted as A9-B45-C1); <br><br> JV-Cvanomethvl-2-cvclohexvlmethvl-jV.jV-diisobutvl-malonamide (Compound 20 13; denoted as A11-B45-C1); <br><br> jV-Cvanomethvl-2-cvclohexvlmethvl-7VjV-diisopropvl-malonamide (Compound 14; denoted as A36-B45-C1); <br><br> JV-Cvanomethvl-2-cvclohexvlmeflivl-iV-r6-methoxv-pvridin-3-vlVmalonamide (Compound 15; denoted as A10-B45-C1); 25 jV-Cvanomethvl-2-cvclohexvlmethvl-iV-(2-tliiophen-2-vl-ethvlVmalonamide <br><br> (Compound 16; denoted as A13-B45-C1); <br><br> jV"-Cvanomethvl-2-cvclohexvlmethvl-JVV3-phenoxv-phenvr)-malonamide (Compound 17; denoted as A14-B45-C1); <br><br> jV-Cvanomethvl-2-cvclohexvlmethvl-jV-C4-nitro-benzvlVmalonamide 30 (Compound 18; denoted as A12-B45-C1); <br><br> N.A/'-Bis-cvanomethvl-2-cvclohexvlmethvl-malonamide (Compound 19; <br><br> 28 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> denoted as A15-B45-C1); <br><br> jV-Cvanomethvl-2-cvclohexvlmethvI-jV-C5.6.7.8-tetrahvdro-naphthalen-l-vlV malonamide (Compound 20; denoted as A17-B45-C1); <br><br> JV-Cvanomethv1-2-cvc1ohexvlmethvl-iV-f2-pvridin-2-vl-ethv1Vma!onamide (Compound 21; denoted as A18-B45-C1); <br><br> TV-Cvanomethvl^-cvclohexvlmethvl-B-^.B-dihvdro-indol-l-vlVS-oxo-propionamide (Compound 22; denoted as A19-B45-C1); <br><br> N-Cvanomethvl-2-cvclohexvlmethvl-3 -(3.4-dihvdro-1 H~isoquinolin-2-vD-3 -oxo-propionamide (Compound 23; denoted as A20-B45-C1); <br><br> iV-Cvanomethvl-2JV-bis-cvclohexvlmethvl-malonamide (Compound 24; denoted as A21-B45-C1); <br><br> iV-Cvanomethvl^-cvclohexvlmethvl-jV-^-methoxv-benzvlVmalonamide (Compound 25; denoted as A22-B45-C1); <br><br> iy-Cvanomethvl-2-cvclohexvlmethvl-iV-( 1 -phenvl-ethvl Vmalonamide (Compound 26; denoted as A23-B45-C1); <br><br> N-Benzvl-N,-cvanomethvl-2-cvclohexvknethvl-jV-methvl-malonamide (Compound 27; denoted as A25-B45-C1); <br><br> iV-Cvanomethvl-2-cvclohexvlmethvl-iV-(3-mtro-benzvlVmalonamide (Compound 28; denoted as A26-B45-C1); <br><br> A^-Cvanomethvl-2-cvclohexvlmethvl-A^-C4-methoxv-benzvlVmalonamide (Compound 29; denoted as A27-B45-C1); <br><br> iV-f3-Caibamovl-phenvlWV1-cvanomethvl-2-cvclohexvlmethvl-ma1onamide (Compound 30; denoted as A28-B45-C1); <br><br> iV-Cvanomethvl-2-cvclohexvlmethvl-iV-pvridin-3-vlmethvl-malonamide (Compound 31; denoted as A16-B45-C1); <br><br> 7/-f4-carbamovlDhenvn-JV-cvanomethvl-2-cvclohexvlmethvlmalonamide (Compound 32; denoted as A29-B45-C1); <br><br> jV-cvanomethvl-2-cvclohexvlmethvl-7V-tetrabvdrofur-2-vlmethv]malonamide (Compound 33; denoted as A30-B45-C1); <br><br> N-cvanomethvl-2-cvclohexvlmethvl-3 -f3 ■4-dihvdro-2i[j'-auinolin-l-vlV3 -oxopTonionamide (Compound 34; denoted as A31-B45-C1); <br><br> 29 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> 7V-/er/-butvI-7\/,-cvanomethvl-2-cvclohexvlmethvl-Miiiethvlmalonamide <br><br> (Compound 35; denoted as A35-B45-C1); <br><br> jV-cvanomethvl-2-cvclohexvlmethvl-A^ -methyl-TV -propvlmalonamide (Compound 36; denoted as A34-B45-C1); 5 TV-butvl-Ar-cvanomethvl-2-cvclohexvlmethvl-iV-methvlmalonamide <br><br> (Compound 37; denoted as A33-B45-C1); <br><br> TV-cvanomethvl-2-cvclohexvlmethvl-iVJV-dimethvlmalonamide (Compound 38; denoted as A32-B45-C1); <br><br> jV-benzvl-jy-cvanomethvl-2-f2-phenvlsulfanvlethvDmalonamide (Compound 10 39; denoted as A2-B80-C1); <br><br> 2-('2rphenvlsulfonvlethvl'&gt;-iV-benzvl-iV-cvanomethvlmalonamide (Compound 40; denoted as A2-B6-C1); <br><br> 2-f2-Benzenesulfonvl-ethvlWV-[(SVl-fl-benzooxazol-2-vl-methanovr&gt;-pentvn-TV-benzvl-malonamide (Compound 41; denoted as A2-B6-C12); 15 Af.A/l-Bis-rfS!-l-fl-benzooxazol-2-vl-methanoviypropvl]-2-cvclohexvlmethvl- <br><br> malonamide (Compound 42; denoted as A37-B45-C13); <br><br> and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual stereoisomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and the N-oxide derivatives, prodrug 20 derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.. <br><br> Pharmacology and Utility: <br><br> The compounds of the invention are selective inhibitors of cathepsin S and, as 25 such, are useful for treating diseases in which cathepsin S activity contributes to the pathology and/or symptomatology of the disease. For example, the compounds of the invention are useful in treating autoimmune disorders, including, but not limited to, juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, Graves' disease, myasthenia gravis, systemic lupus erythemotasus, rheumatoid arthritis and Hashimoto's 30 thyroiditis, allergic disorders, including, but not limited to, asthma, and allogeneic immune responses, including, but not limited to, organ transplants or tissue grafts. <br><br> Cathepsin S also is implicated in disorders involving excessive elastolysis, such as <br><br> 30 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> chronic obstructive pulmonary disease (e.g., emphysema), bronchiolitis, excessive airway elastolysis in asthma and bronchitis, pneumonities and cardiovascular disease such as plaque rupture and atheroma. Cathepsin S is implicated in fibril formation and, therefore, inhibitors of cathepsins S are of use in treatment of systemic amyloidosis. <br><br> 5 The cysteine protease inhibitory activities of the compounds of the invention can be determined by methods known to those of ordinary skill in the art. Suitable in vitro assays for measuring protease activity and the inhibition thereof by test compounds are known. Typically, the assay measures protease induced hydrolysis of a peptide based substrate. Details of assays for measuring protease inhibitory activity are set forth in 10 Examples 6-9, infra. <br><br> Administration and Pharmaceutical Compositions: <br><br> In general, compounds of Formula I will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly 15 . or in combination with one or more therapeutic agents. A therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. For example, therapeutically effective amounts of a compound of Formula I may range from about 1 micrograms per kilogram body weight (|ig/kg) per day to about 1 milligram per kilogram 20 body weight (mg/kg) per day, typically from about 10 fig/kg/day to about 0.1 mg/kg/day. <br><br> Therefore, a therapeutically effective amount for a 80 kg human patient may range from about 100 jig/day to about 100 mg/day, typically from about 1 (ig/day to about 10 mg/day. <br><br> In general, one of ordinary skill in the art, acting in reliance upon personal knowledge and the disclosure of this Application, will be able to ascertain a therapeutically effective 25 amount of a compound of Formula I for treating a given disease. <br><br> * <br><br> The compounds of Formula I can be administered as pharmaceutical compositions by one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository) or parenteral (e.g., intramuscular, intravenous or subcutaneous). Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained 30 release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate composition and are comprised of, in general, a compound of Formula I in combination <br><br> 31 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the active ingredient. Such excipient may be any solid, liquid, semisolid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art. <br><br> 5 Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, <br><br> sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearates, glycerol monostearate, sodium chloride, dried skim milk, and the like. Liquid and semisolid excipients may be selected from water, ethanol, glycerol, propylene glycol and various oils, including those of petroleum, animal, vegetable or synthetic origin (e.g., 10 peanut oil, soybean oil, mineral oil, sesame oil, and the like). Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose and glycols. <br><br> Hie amount of a compound of Formula I in the composition may vary widely depending upon the type of formulation, size of a unit dosage, kind of excipients and other factors known to those of skill in the art of pharmaceutical sciences. In general, a 15 composition of a compound of Formula I for treating a given disease will comprise from 0.01%w to 10%w, preferably 0.3%w to l%w, of active ingredient with the remainder being the excipient or excipients. Preferably the pharmaceutical composition is administered in a single unit dosage form for continuous treatment or in a single unit dosage form ad libitum when relief of symptoms is specifically required. Representative 20 pharmaceutical formulations containing a compound of Formula I are described in Example 10. <br><br> 25 <br><br> Chemistry: <br><br> Processes for Making Compounds of Formula I: <br><br> i <br><br> Compounds of the invention may be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, for example those described by R.C. Larock in Comprehensive Organic Transformations, 30 VCH publishers, 1989. <br><br> In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these <br><br> 32 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991. <br><br> Compounds of Formula I, where X1 is -NHC(R')(R2)X2, can be prepared by proceeding as in the following Reaction Scheme 1: <br><br> Reaction Scheme 1 <br><br> nh2cr'r2x2 <br><br> VvSrS <br><br> o o r1 i in which X2, R1, R2, R3 and R4 are as defined in the Summary of the Invention. <br><br> Compounds of Formula I can be prepared by condensing an acid of Formula 2 with a compound of formula NH2CR'R2X2. Hie condensation reaction can be effected with an appropriate coupling agent (e.g., benzotriazol-l-yloxytrispyrrolidino-phosphonium hexafluorophosphate (PyBOP®), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), O-benzotriazol-1 -yl-NJSfJf -tetramethyluronium hexafluorophosphate (HBTU), 1,3-dicyclohexyl-carbodiimide (DCC), or the like) and optionally an appropriate catalyst (e.g., 1-hydroxybenzotriazole (HOBt), l-hydroxy-7-azabenzotriazole (HOAt), or the like) and non-nucleophillic base (e.g., N-methylmorpholine, triethylamine, or the like, or any suitable combination thereof) in a suitable solvent (N-methylpyrrolidinone, or the like) at ambient temperature and requires <br><br> 33 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> 3 to 10 hours to complete the reaction. A detailed description for the synthesis of a compound of Formula I by the processes in Reaction Scheme 1 is set forth in the Examples, infra. <br><br> Compounds of Formula I, where X1 is -NHX3, can be prepared by proceeding as in the following Reaction Scheme 2: <br><br> Reaction Scheme 2 <br><br> nh2x3 <br><br> ' r <br><br> -yV1' <br><br> o o i <br><br> in which X3, R3 and R4 are as defined in the Summary of the Invention. <br><br> • Compounds of Formula I can be prepared by condensing an acid of Formula 2 with a compound of formula NH2X3. The condensation reaction can be effected with an appropriate coupling agent (e.g., benzotriazol-l-yloxytrispyrrolidino-phosphonium hexafluorophosphate (PyBOP®), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), O-benzotriazol-1 -yl-NJfJf Jf -tetramethyluronium hexafluorophosphate (HBTU), 1,3-dicyclohexyl-carbodiimide (DCC), or the like) and optionally an appropriate catalyst (e.g., 1-hydroxybenzotriazole (HOBt), l-hydroxy-7-azabenzotriazole (HOAt), or the like) and non-nucleophillic base (e.g., N-methylmorpholine, triethylamine, or the like, or any suitable combination thereof) in a suitable solvent (JV-methylpyrroUdinone, or the like) at ambient temperature and requires <br><br> 34 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> 3 to 10 hours to complete the reaction. A detailed description for the synthesis of a compound of Formula I by the processes in Reaction Scheme 1 is set forth in the Examples, infra. <br><br> 5 Additional Processes for Preparing Compounds of Formula I: <br><br> A compound of Formula I can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid. Alternatively, a phannaceutically acceptable base addition salt of a compound of Formula I can be prepared by reacting the free acid form 10 of the compound with a pharmaceutically acceptable inorganic or organic base. Inorganic and organic acids and bases suitable for the preparation of the pharmaceutically acceptable salts of compounds of Formula I are set forth in the definitions section of this Application. Alternatively, the salt forms of the compounds of Formula I can be prepared using salts of the starting materials or intermediates. <br><br> 15 The free acid or free base forms of the compounds of Formula I can be prepared from the corresponding base addition salt or acid addition salt form. For example, a compound of Formula I in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like). A compound of Formula I in a base addition salt form can be 20 converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc). <br><br> The N-oxides of compounds of Formula I can be prepared by methods known to those of ordinary skill in the art. For example, iV-oxides can be prepared by treating an unoxidized form of the compound of Formula I with an oxidizing agent (e.g., 25 trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0°C. Alternatively, the TV-oxides of the compounds of Formula I can be prepared from the N-oxide of an appropriate starting material. <br><br> 30 Compounds of Formula I in unoxidized form can be prepared from N-oxides of compounds of Formula I by treating with a reducing agent (e.g., sulfur, sulfur dioxide, <br><br> 35 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in an suitable inert organic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80°C. <br><br> Prodrug derivatives of the compounds of Formula I can be prepared by methods 5 known to those of ordinary skill in the art (e.g., for further details see Saulnier et a/. (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985). For example, appropriate prodrugs can be prepared by reacting a non-derivatized compound of Formula I with a suitable caibamylating agent (e.g., 1,1 -acyloxyalkylcarbonochloridate, /wra-nitrophenyl carbonate, or the like). <br><br> 10 Protected derivatives of the compounds of Formula I can be made by means known to those of ordinary skill in the art. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T.W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley &amp; Sons, Inc. 1999. Compounds of the present invention may be conveniently prepared, or formed during the 15 process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallisation from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol. Compounds of Formula I can be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair 20 of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomer. While resolution of enantiomers can be carried out using covalent diasteromeric derivatives of compounds of Formula I, dissociable complexes are preferred (e.g., crystalline diastereoisomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily 25 separated by taking advantage of these dissimilarities. The diastereomers can be separated by chromatography or, preferably, by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of 30 compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley &amp; Sons, Inc. (1981). <br><br> 36 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> In summary, the compounds of Formula I are made by a process which comprises: (A) reacting a compound of Formula 2: <br><br> 2 <br><br> with a compound of formula NHjCR'R^X2, in which R1, R2, R3, R4 and X2 are as defined in the Summary of the Invention for Formula I; or <br><br> (B) reacting a compound of Formula 2 with a compound of Formula NH2X3, in which R3, R4 and X3 are as described in the Summary of the Invention for Formula I; and <br><br> (C) optionally converting a compound of Formula I into a pharmaceutically acceptable salt; <br><br> (D) optionally converting a salt form of a compound of Formula I to non-salt form; <br><br> (E) optionally converting an unoxidized form of a compound of Formula I into a pharmaceutically acceptable JV-oxide; <br><br> (F) optionally converting an jV-oxide form of a compound of Formula I its unoxidized form; <br><br> (G) optionally resolving an individual isomer of a compound of Formula I from a mixture of isomers; <br><br> (H) optionally converting a non-derivatized compound of Formula I into a pharmaceutically prodrug derivative; and <br><br> (I) optionally converting a prodrug derivative of a compound of Formula I to its non-derivatized form. <br><br> Examples: <br><br> The present invention is further exemplified, but not limited by, the following examples that illustrate the preparation of compounds of Formula I (Examples) and intermediates (References) according to the invention. <br><br> 37 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> REFERENCE 1 2-Phenvlcarbamovl-hexanoic acid <br><br> A solution of aniline (5.47 ml, 60 mmol) and triethylamine (8.36 ml, 60 mmol) 5 in methylene chloride (150 ml) was cooled to -20°C and treated with methylmalonylchloride (8.36 ml, 60mmol) in methylene chloride (20 ml). The reaction mixture was allowed to warm to ambient temperature for 3 hours and then poured into cold IN HC1. The organic layer was separated and washed with aqueous sodium bicarbonate then brine and dried over magnesium sulfate and evaporated to give methyl 10 2-phenylcarbamoylacetate. <br><br> A mixture of methyl 2-phenylcarbamoylacetate (1.159g, 6 mmol) lithium hydroxide (0.43g, 18 mmol) and 1-iodobutane (0.91 ml, 8 mmol) in TV-methylpyrrolidinone (10 ml) was stirred at ambient temperature for 1.5 hours. The reaction mixture was poured into ice water, extracted with ethylacetate (twice, 50 ml each). The combined extracts were 15 washed with brine, dried over magnesium sulfate and evaporated. The residue was purified by flash chromatography on silica gel eluting with 20% ethylacetate/hexane to give methyl 2-phenylcarbamoylhexanoate (0.715g, 48% yield). <br><br> A solution of methyl 2-phenylcarbamoylhexanoate (0.98g 3.9 mmol) in methanol (10 ml) was treated with sodium hydroxide (4 ml, 4 mmol) at ambient temperature for 17 20 hours. The methanol was removed under reduced pressure and the residue was treated with IN HC1 and extracted with ethylacetate (twice, 50 ml each). The organic layers were washed with brine, dried over magnesium sulfate and evaporated to give 2z nhenvlcarbamovlhexanoic acid (0.68 g, 2.9 mmol, 74% yield). <br><br> 25 <br><br> REFERENCE 2 2-Cvclohexvlmethvl-iV-phenvl-malonamic acid <br><br> A mixture of methyl 2-phenylcarbamoylacetate (prepared as in reference Example 30 1) (4.39 g, 22.7 mmol), lithium hydroxide (1.08 g, 45 mmol) and bromomethylcyclohexane (3.76 ml, 27 mmol), in iV-methylpyrrolidinone (25 ml) was stirred at ambient temperature <br><br> 38 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> for 17 hours. The reaction mixture was poured into ice water and extracted with ether (three times, 100 ml each). The extracts were washed with water then brine, dried over magnesium sulfate and evaporated. The residue was purified by flash chromatography on silica gel eluting with 10% ethylacetate (hexane) to give methyl 2-cyclohexylmethyWV-5 phenyl malonamate (1.89 g, 6.5 mmol, 29% yield). The aqueous layer above was cooled on ice and acidified to pH 2 with IN HC1. The aqueous layer was extracted with ether (3 times, 100 ml each) and the extracts were washed with water, then brine, dried over magnesium sulfate and evaporated to give 2-cvclohexvlmelhvl-jV-phenvl malonamic acid (1.12 g, 18% yield). <br><br> REFERENCE 3 2-Cvclohexvlmethvl-7V-phenethvl-malonamic acid <br><br> Sodium (6.9 g, 0.3 mol), dissolved in ethanol (300 ml), and then diethylmalonate (50.3 ml, 0.3 mol) was added. Bromomethylcyclohexane (46 ml, 0.33 mol) was added and the reaction mixture was heated at 70°c for 14 hours. The reaction mixture was cooled and the ethanol removed by evaporation. The resulting mass was dissolved in ice water and then extracted with ethylacetate. The organic layers were washed with water, then brine and dried over magnesium sulfate. The solvents were removed under reduced pressure to give diethylcyclohexyl malonate. <br><br> A solution of diethylcyclohexylmalonate (12.8 g, 0.05 mol) in ethanol (100 ml) was treated with a solution of lithium hydroxide (1.2 g, 0.05 moles) in water (50 ml) and then stirred at ambient temperature for 15 hours. The ethanol was removed at reduced pressure and water (50 ml) was added to the residue. The reaction mixture was extracted wife ether, 25 cooled on ice and acidified to pH 1.5 with HC1. The aqueous phase was saturated with NaCl and extracted with ethylacetate (twice, 150 ml each). Drying over magnesium sulfate and evaporating the solvent gave ethyl 2-cyclohexylmalonate (8.52 g, 37 mmol, 74% yield). <br><br> The ethyl 2-cyclohexylmalonate (8.52 g, 37 mmol) in ethylacetate (80 ml) was 30 cooled to 0° C and treated with dimethylformade (50p.L) and then oxalylchloride (3.93 ml, 45 mmol). The reaction temperature was raised to room temperature and after 2 hours the <br><br> 15 <br><br> 20 <br><br> 39 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> solvents were removed under reduced pressure to give ethyl 2-cyclohexylmalonyl chloride. <br><br> The malonylchloride above was diluted to 28 ml volume with ethylacetate and 2 ml of that solution was added to a solution of phenethylamine (0.376 ml, 3 mmol) and N-methylmorpholine (0.40 g, 4 mmol) in ethylacetate (4 ml) at -20°c. After 15 minutes the 5 reaction mixture was allowed to warm to ambient temperature overnight. The reaction mixture was diluted with ethylacetate (5 ml) and ice water (5 ml). The organic layer was separated and washed with cold 0.05 N HC1, then aqueous NaHC03, then brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by radial chromatography to give ethyl 2-cyclohexyhnethyl-N-phenethyl malonamate (0.366 10 g, 1.10 mmol, 42% yield). <br><br> The ester above (0.366 g, 1.10 mmol) in ethanol (10 ml) was treated at ambient temperature with aqueous sodium hydroxide (1.3 ml of IN) for 2.5 hours. The reaction mixture was diluted with water (30 ml) and washed with ether (3 times, 30 ml each). The aqueous layer was cooled, acidified with IN HC1 (2 ml) and extracted with ethylacetate 15 (3 times, 30 ml each). The ethylacetate extracts were washed with brine, dried over magnesium sulfate and evaporated to give 2-cvclohexvlmethvl-iV-phemethvlmalonamic acid (0.138 g, 0.46 mmol, 42% yield). <br><br> REFERENCE 4 2-Cvclohexvlmethvl-iV-pvridin-4-vhnethvl-malonamic acid <br><br> Ethyl 2-cyclohexylmethylmalonyl chloride, prepared as in Reference 3 (0.307 g, 1.25 mmol), was condensed with 4-aminomethyl pyridine using the method of Reference 3 to give ethyl 2-cyclohexyImethyl-4-pyrin-4-ylmethylmalonamate (0.237 g, 0.74 mmol, 58% yield). <br><br> This ester was hydrolyzed with sodium hydroxide using the method of Reference 3 to give 2-cvclohexvlmethvl-jV-pvridin-4-vlmethvlmalonamic acid (0.041 g, 0.14 mmol, 19% yield). <br><br> Proceeding as in the above referenced examples provided the following compounds: <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 40 <br><br> 02/098406 <br><br> PCT/US02/17922 <br><br> A^-Benzyl-2-cyclohexylmethyl-malonamic acid; 2-Cyclohexylmethyl-iV-(4-phenoxy-phenyl)-malonamic acid; 2-Cyclohexylmethyl-iV-(3 -phenyl-propyl)-malonamic acid; 2-Cyclohexylmethyl-3-moipholin-4-yl-3-oxo-propiomc acid; TV-Cyclohexyl-2-cyclohexylmethyl-malonamic acid; 2-Cyclohexylmethyl-7V-naphthalen-l-ylmethyl-malonamic acid; 2-Cyclohexylmethyl-Ar-pyridin-3-yl-maIonaxmc acid; 2-Cyclohexylmethyl-A^V-diisobutyl-malonamic acid; 2-Cyclohexylmethyl-TV-(6-methoxy-pyridin-3-yl)-malonamic acid; 2-CyclohexyImethyl-A''-(2-thiophen-2-yl-ethyl)-malonamic acid; 2-Cyclohexylmethyl-iV-(3-phenoxy-phenyl)-maIonamicacid; 2-Cyclohexylmethyl-Ar-(4-mtro-benzyl)-malonamic acid; iV-Cyanomethyl-2-cyclohexylmethyl-malonamic acid; 2-Cyclohexybnethyl-Ar-(5,6,7,8-tetrahydro-naphthalen-l-yl)-malonamic acid; 2-CycIohexylmethyl-JV-(2-pyridin-2-yl-ethyl)-malonamic acid; 2-Cyclohexylmethyl-3-(2,3-dihydro-ixidol-l-yl)-3-oxo-propionic acid; 2-Cyclohexylmethyl-3-(3,4-dihydro-lJ^-isoquinolin-2-yl)-3-oxo-propionic acid; 2^-Bis-cyclohexylmethyl-3-oxo-butyramide; 2-Cyclohexylmethyl-iV-(2-methoxy-benzyl)-3-oxo-butyramide; 2-Cyclohexylmethyl-7V-( 1 -phenyl-ethyl)-malonamic acid; iV-Benzyl-2-cyclohexylmethyl-JV-methyl-maionamic acid; 2-CyclohexyImethyl-7V-(3-nitro-ben2yl)-3-oxo-butyramide; 2-Cyclohexylmethyl-iV-(4~methoxy-benzyl)-malonamic acid; iV-(3-Carbamoyl-phenyl)-2-cyclohexylmethyl-malonamic acid; 2-Cyclohexylmethyl-iV'-pyridin-3-ylmethyl-malonamic acid; iV-(4-Carbamoyl-phenyl)-2-cyclohexyliiiethyl-nialonamicacid; 2-Cyclohexylmethyl-iV-(tetrahydro-furan-2-ylmethyl)-malonamicacid; 2-Cyclohexylmethyl-3-(3,4-dihydro-2/f-quinolin-l -yl)-3-oxo-propionic acid; TV-^rt-Butyl-2-cyclohexylmethyl-iV-methyl-malonatiiic acid; 2-Cyclohexylmethyl-iV'-methyl-Ar-propyl-malonamic acid; 7V-Butyl-2-cyclohexylmethyl-JV-methyl-malonamic acid; <br><br> 41 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> 2-Cyclohexyhnethyl-iV,Ar-dimethyl-malonamic acid; (R)-2-Benzylcarbamoyl-4-phenylsulfanyl-butyric acid; and 4-Benzenesulfonyl-2-benzylcarbamoyl-butyricacid; <br><br> EXAMPLE 1 2-butvl-jV-cvanomethvl-iV-phenvlmalonamide (Compoimd 1) <br><br> A solution comprised of 2-Phenylcarbamoyl-hexanoic acid (188g, 0.8mmol), prepared as in Reference 1, in DMF (5.0mL) wastreated with PyBOP® (425 0.8mmol), aminoacetonitrile bisulfate (140mg, 0.9 mmol) and triethylamine (600jjL, 4.3mmol). The mixture was stirred for 3 hours and then partitioned between water (20 mL) and ethyl acetate (50 mL). The organic layer was separated and washed wife 1M saturated sodium bicarbonate solution, 1 M hydrochloric acid solution and water, dried (MgS04) and concentrated. Product was purified from the residue by flash column on silica gel (60°A) wife 50% ethyl acetate in hexane to provide 2-butvl-N-cvanomethvl-N,-phenvlmalonamide (125 mg, 57% yield).. lH NMR: (DMSO) 10.01 (s, 1H), 7.59 (d, J=8Hz, 2H), 7.31 (t, J=7Hz, 2H), 7.06 (t, J=7Hz, 1H), 4.13 (d, J=6Hz, 2H), 3.32 (t, J=8Hz, 1H), 1.80 (m, 2H), 1.25 (m, 4H), 0.86 (t, J=7Hz, 3H). MS: m/e 273.9. <br><br> EXAMPLE 2 <br><br> A^-Cvanomethvl-2-cvclohexvlmethvl-iV-phenvl-malonamide (Compound 2); <br><br> 42 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> A solution comprised of 2-Cyclohexylmetib.yl-iV-phenyl-malonamic acid (350 mg, <br><br> 1.2 mmol), prepared as in Reference 2, EDCI (250 mg, 1.3 mmol), HOBt hydrate (199 mg, <br><br> 1.3 mmol), amino acetonitrile bisulfate (200 mg, 1.3 mmol) and N-methylmorpholine (0.30 ml, 2.7 mmol) huY TV-dimethylpyrrolidinone (5 ml) was stirred at ambient temperature for 15 hours. The reaction mixture was poured into cold IN HC1 and extracted with ethylacetate. The organic phase was washed with aqueous saturated sodium bicarbonate and then brine (50 ml each) dried over magnesium sulfate and evaporated. The residue was purified by radial chromatography using 50% ethylacetate/hexane as eluent to provide N-Cvanomethvl-2-cvclohexvlmethvl-N'-phenvl-malonamide (179 mg, 48% yield). lH NMR: (DMSO) 10.01 (s, 1H), 8.47 (t, J=5Hz, 1H), 7.59 (d, J=7Hz, 2H), 7.31 (t, J=8Hz, 2H), 7.07 (t, J=7Hz, 1H), 4.13 (d, J=5Hz, 2H), 3.47 (t, J=7Hz, 1H), 1.6 (m, 7H), 1.1 (m, 4H), 0.9 (m, 2H). MS: m/e 313.2. <br><br> EXAMPLE 3 <br><br> A/-cvanomethvl-2-cvclohexvlmethvl-Ar-phenethvlmalonamide (Compound 3) <br><br> A solution comprised of 2-Cyclohexylmethyl-iV-phenethyl-malonic acid (138 mg, 0.46 mmol), prepared as in Reference 3, EDCI (115 mg, 0.60 mmol), HOBt hydrate (92 mg, 0.60 mmol), N-methylmorpholine (0115 ml, 1.38 mmol) in iV,jV-dimethyl pyrrolidimone (4 ml) was stirred at ambient temperature for 10 min. Aminoacetonitrile bisulfate (106 mg, 0.69 mmol) was added. The reaction mixture was stirred at ambient temperature for 2 hours, then poured into cold IN HC1 and extracted twice with ethylacetate (50 ml each). The organic phase was washed with aqueous sodium bicarbonate and then brine (50 ml each), dried over magnesium sulfate and evaporated. <br><br> 43 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> The residue was purified by radial chromatography using 50% ethylacetate/hexane as eluent to provide Ar-cvanomethvl-2-cvclohexvlomethvl-AP-phenethvhnalonamide (56 mg, 36% yield), 'HNMR: (DMSO) 8.38 (t, J=5Hz, 1H), 7.98 (t, J=6Hz, 1H), 7.25 (m, 5H), 4.10 (d, J=6Hz, 2H), 3.2 (m, 3H), 2.71 (t, J=7Hz, 2H), 1.6 (m, 7H), 1.1 (m, 4H), 0.85 (m, 5 2H). MS: m/e 342.10. <br><br> EXAMPLE 4 <br><br> A^-cvanomethvl-2-cvclohexvlmethvl-JV-pvrid-4-vlmethvlmalonamide <br><br> (Compound 4) <br><br> 10 <br><br> A solution comprised of 2-Cyclohexylmethyl-JV-pyridin-4-yhnethyl-malonic acid (41 mg, 0.14 mmol), prepared as in Reference 4, was coupled to aminoacetonitrile as described in Example 3 to provide A/-cvanomethvl-2-cvclohexvlmethvl-jV-pvrid-4-vlmethvlmalonamide (13 mg, 28% yield). 'HNMR: (DMSO) 8.5 (m, 4H), 7.20 (d, J=6Hz, 15 2H), 4.3 (m, 2H), 4.13 (d, J=5Hz, 2H), 3.3 (m, 1H), 1.6 (m, 7H), 1.1 (m, 4H), 0.83 (m, 2H). MS: m/e 329.08. <br><br> EXAMPLE 5 <br><br> 20 TV-f 1 -VI -Benzooxazol-2-vl-methanovlV3-phenvl-propvll-7V-benzvl-2- <br><br> cvclohexvhnethvl-malonamide (Compound 5) <br><br> 44 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> OJ , <br><br> o <br><br> A mixture of iV-benzyl-2-cyclohexylmethyl-malonamic acid (200mg, 0.69mmol), HOBt (159mg, 1.04mmol), EDC (146mg, 0.76mmol), 2-amino-l-benzooxazol-2-yl-4-phenyl-butan-1 -one (195mg, 0.69mmol), dichloromethane (3mL) and triethylamine (106jj,L, 0.76mmol) was allowed to stir 2 hour. The product was extracted into ethyl acetate (6QmL) and washed with two 15mL portions of IN HC1, and two 15mL portions of saturated NaHS03, dried over MgS04 and concentrated. Ethyl acetate (5mL) was added and a white precipitate formed and was collected to give jV-[i-(i-benzooxazol-2-yl-l-hydroxy-methyl)-3-phenyl-propyl]-JV-benzyl-2-cyclohexylmethyl-malonamide (81mg, 0.12mmol, 21% yield). <br><br> N-[l-(l-Benzooxazol-2-yl-l-hydroxy-methyl)-3-phenyl-propyl]-iV-benzyl-2-cyclohexylmethyl-malonamide (70mg, 0.126mmol) was dissolved in 0.6mL dichloromethane and treated with Dess Martin periodinane (107mg, 0.253mmol). The mixture was stirred for 2 hours, then 8mL of 0.26M NaS203 in saturated NaHS03 was added and the mixture was extracted with two 15mL portions of ethyl acetate and washed with two 4mL portions of saturated NaHS03. The organic layer was dried over MgS04 and concentrated. The product was recrystallized from ethyl acetate and hexane to give AT-f 1 -f 1 -Benzooxazol-2-vl-methanovlV3-phenvl-propvr|-jV-benzvl-2-cvclohexvlmethvl-malonamide (40mg, 0.072mmol, 57% yield); 'HNMR: (DMSO) 7.88 (m, 1H), 7.68-7.40 (m, 3H), 7.35-7.10 (m, 10H), 6.90 (m, 1H), 5.65 (m, 1H), 4.43 (d, J=5.7Hz, 2H), 3.25 (m, 1H), 2.74 (t, J=8.0Hz, lH), 2.46 (m, 1H), 2.17 (m, 1H), 1.77 (t, J=7.4Hz, 1H), 1.64 (m, 7H), 1.22 (m, 4H), 0.87 (m, 2H); MS: (M++l) 552.8; 551.68. <br><br> The following compounds of Formula I were provided by proceeding as in the above Examples: <br><br> 45 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> A^cvanQmethvl-iV-cvclohexvl^-cvclohexvlmethvlmalonamide (Compound 6); *H NMR(DMSO): 8.31 (t, J=6Hz, 1H), 7.82 (d, J=8Hz, 1H), 4.10 (d, J=8Hz, 2H), 3.52 (m, IH), 3.20 (t, J=7Hz, IH), 1.6 (m, 12H), 1.1 (m, 9H), 0.83 (m, 2H); MS (m/e) =320.11; <br><br> N-benzvl-Ar-cvanomethvl-2-cvclohexvlmethvlmalonamide (Compound 7); 'H 5 NMR(DMSO): 8.45 (m, 2H), 7.3 (m, 5H), 4.33 (dd, J=6,15Hz, IH), 4.23 (dd, J=6,15Hz, 1H), 4.12 (d, 2H), 3.3 (m, IH), 1.6 (m, 7H), 1.1 (m, 4H), 0.85 (m, 2H); MS (m/e) = 328.15, M.Wt. = 327.43; <br><br> N-cvanomethvl-2-cvclohexvlmethvl-AP -(4-phenoxvphenvDmalonamide (Compound 8); *13 NMR(DMSO): 10.1 (s, 1H), 8.50 (t,J=5Hz, IH), 7.61 (d, J=7Hz, 2H), 10 7.37 (t, J=7Hz, 2H), 7.11 (t,J=7Hz, IH), 7.0 (m, 4H), 4.14 (d, J=5Hz, 2H), 3.47 (U=7Hz, IH), 1.7 (m, 7H), 1.1 (m, 4H), 0.92 (m, 2H); MS (m/e) = 406.10, M.Wt. = 405.49; <br><br> iV-cvanomethvl-2-cvclohexvlmethvl-JV-f3-phenvlpropvl'taialonamide (Compound 9); *H NMR(DMSO): 8.38 (t, J=6Hz, IH), 8.00 (t,J=6Hz, IH), 7.2 (m, 5H), 4.10 (d, J=5Hz, 2H), 3.23 (t,J=7Hz, IH), 3.1 (m, 2H), 2.5 (m, 2H), 1.6 (m, 9H), 1.1 (m, 4H), 0.85 15 (m, 2H); MS (m/e) = 356.02; <br><br> 7V-cvanomethvl-2-cvclohexvlmethvl-3-morpholin-4-vl-3-oxopropionamide (Compound 10); 'H NMR(DMSO): 8.54 (t, J=4Hz, IH), 4.12 (d, J=5Hz, 2H), 3.5 (m, 8H), 1.65 (m, 8H), 1.15 (m, 4H), 0.85 (m, 2H); MS (m/e) = 308.05; <br><br> Af-cvanomethvl-2-cvclohexvlmethvl-AP-naphth-1 -vlmethvlmalonamide (Confound 20 11); 'H NMR(DMSO): 8.53 (t, J=5Hz, IH), 8.43 (t,J=6Hz, IH), 8.04 (m, IH), 7.94 (m, IH), 7.86 (d,J=8Hz, IH), 7.5 (m, 4H), 4.85 (dd, J=6,15Hz, IH), 4.65 (dd, J=5,15Hz, IH), 4.12 (d, J=3Hz, 2H), 3.3 (m, IH), 1.6 (in, 8H), 1.0 (m, 5H); MS (m/e) = 378.18, M.Wt. 377.18; <br><br> iV-cvanomethvl-2-cvclohexvlmethvl-jV-Pvrid-3-vlmalonamide (Compound 12); 25 NMR(DMSO): 10.24 (s, IH), 8.75 (s, IH), 8.54 (t, J=5Hz, IH), 8.29 (d, J=5Hz, IH), 8.04 (d,J=7Hz, IH), 7.36 (m, IH), 4.13 (d, J=5Hz, 2H), 3.49 (t, J=7Hz, IH), 1.7 (m, 7H), 1.1 (m, 4H), 0.9 (m, 2H); MS (m/e) = 314.91; <br><br> j\r-cvanomethvl-2-cvclohexvlmethvl-jVJV-diisobutvlmalonamide (Compound 13); 'H NMR(DMSO): 8.50 (t, J=4Hz, IH), 4.09 (m, 2H), 3.63 (t, J=7Hz, IH), 3.2 (m, 2H), 30 3.05 (m, 2H), 1.9 (m, 2H), 1.6 (m, 7H), 1.1 (m, 4H), 0.8 (m, 14H); MS (m/e) = 350.08, M.Wt. 349.51; <br><br> 46 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> j\T-cvanome1favl-2-cvclohexvlmethvl-iV'jV'-diisopropvlnialonamide (Compound 14); 1H&gt;MR(DMSO): 8.45 (t, J=5Hz, IH), 4.1 (m, 3H), 3.55 (t, J=7Hz, IH), 3.46 (m, IH), 1.6 (m, 7H), 1.27 (d, J=7Hz, 6H), 1.11 (m, 10H), 0.85 (m, 2H); MS (m/e) = 321.99, M.Wt. 321.24; <br><br> 5 A/,-cvanomethvl-2-cvclohexvlmethvl-A^-C6-methoxvPvrid-3-vl')malonamide <br><br> (Compound 15); 'H NMR(DMSO): 10.04 (s, IH), 8.50 (t, J=5Hz, IH), 8.35 (s, IH), 7.88 (d, J=9Hz, IH), 6.80 (d,J=9Hz, IH), 4.13 (m, 2H), 3.81 (s, 3H), 3.44 (t, J=8Hz, IH), 1.7 (m, 7H), 1.1 (m, 4H), 0.91 (m, 2H); MS (m/e) = 345.01, M.Wt. 344.18; <br><br> i\r-cvanomethvl-2-cvclohexvlmethvl-iV-f2-thien-2-vlethvl'&gt;malonamide(,ComD0und 10 16); 'H NMR(DMSO): 8.40 (t, J=5Hz, IH), 8.07 (t, J=5Hz, IH), 7.33 (d, J=5Hz, IH), 6.95 (m, IH), 6.87 (m, IH), 4.10 (d, J=5Hz, 2H), 3.3 (m, 3H), 3.21 (t, J=7Hz, 2H), 1.6 (m, 7H), 1.1 (m, 4H), 0.85 (m, 2H); MS (m/e) = 348.09, M.Wt. 347.48; <br><br> jy-cvanomefovl-2-cvclohexvlmethvl-AP-f3-phenoxvphenvDmalonamide (Compound 17); 'H NMR(DMSO): 10.1 (s, IH), 8.45 (t, J=5Hz, IH), 7.41 (t, J=8Hz, 2H), 15 7.33 (m, 3H), 7.16 (t, J=7Hz, IH), 7.03 (d, J=8Hz, 2H), 6.73 (m, IH), 4.1 (m, 2H), 3.42 (t, J=7Hz, IH), 1.6 (m, 7H), 1.1 (m, 4H), 0.85 (m, 2H); MS (m/e) = 406.04, M.Wt. 405.49; <br><br> jy-cvanomethvl^-cvclohexvlmethvl-iV-^-nitrobenzvnmalbnamide (Compound 18); 'H NMR(DMSO): 8.61 (t, J=6Hz, IH), 8.53 (t, J=6Hz, IH), 8.17 (d, J=9Hz, 2H), 7.47 (d, J=9Hz, 2H), 4.41 (d, J=6Hz, 2H), 4.14 (d, J=6Hz, 2H), 3.3 (m, IH), 1.6 (m, 7H), 1.1 20 (m, 4H), 0.87 (m,2H); MS (m/e) = 373.02, M.Wt. 372.42; <br><br> iVJV-biscvanomethvl-2-cvclohexvlmethvlmalonamide (Compound 19); 'H NMR(DMSO): 8.59 (t, J=5Hz, 2H), 4.14 (d, J=6Hz, 4H), 3.28 (t, J=8Hz, IH), 1.6 (m, 7H), 1.1 (m, 4H), 0.86 (m, 2H); MS (m/e) = 276.99, M.Wt. 276.34; <br><br> iV-cvanomethvl-2-cvclohexvlmethvl-iV,-f5.6.7.8-tettahvdronaphth-l-vl'ta?a1nnamide 25 (Compound 20); 'H NMR(DMSO): 9.28 (s, IH), 8.57 (t, J=6Hz, IH), 7.21 (d, J=8Hz, IH), 7.05 (t, J=8Hz, IH), 6.90 (d, J=7Hz, IH), 4.16 (d, J=6Hz, 2H), 3.49 (t, J=7Hz, IH), 2.7 (m, 2H), 2.5 (m, 2H), 1.7 (m, 11H), 1.1 (m, 4H), 0.91 (m, 2H); MS (m/e) = 368.04, M.Wt. 367.48; <br><br> j^-cvanomethvl-2-cvclohexvlmeflivI-iV-(2-pvrid-2-vlethvnmalonamide 30 (Compound 21); 'H NMR(DMSO): 8.49 (m, IH), 8.40 (t, J=6Hz, IH), 8.00 (t, J=5Hz, IH), 7.68 (dt, J=2,8Hz, IH), 7.2 (m, 2H), 4.09 (d, J=6Hz, 2H), 3.42 (m, 2H), 3.17 (t, J=8Hz, <br><br> 47 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> IH), 2.85 (t, J=7Hz, 2H), 1.6 (m, 7H), 1.07 (m, 4H), 0.83 (m, 2H); MS (m/e) = 343.04, M.Wt. 342.44; <br><br> 7V-cvanomethvl-2-cvclohexvlmethvl-3-f2.3-dihvdroindol-l-vlV3-oxopropionamide (Compound 22); 'H NMR(DMSO): 8.73 (t, J=5Hz, IH), 8.06 (d, J=8Hz, IH), 7.24 (d, 5 J=7Hz, IH), 7.15 (t, J=7Hz, IH), 7.00 (t, J=7Hz, IH), 4.15 (d, J=5Hz, 2H), 4.1 (m, 2H), 3.66 (t, J-7Hz, IH), 3.14 (in, 2H), 1.6 (m, 7H), 1.1 (m, 4H), 0.91 (m, 2H); MS (m/e) = 340.07, M.Wt. 339.19; <br><br> JV-cvanomethvl-2-cvclohexvlmethvl-3-f3.4-dihvdro-lJy-isoquinolin-2-vlV3-oxopropionamide (Compound 23); 'H NMR(DMSO): 8.64(t, J=5Hz, IH), 7.15 (s, 4H), £ 10 4.65 (m, 2H), 4.11 (t, J=6Hz, 2H), 3.77 (m, 2H), 2.8 (m, 2H), 1.7 (m, 7H), 1.1 (m, 4H), 0.89 (m, 2H), 3.54 (m, IH); MS (m/e) = 354.05, M.,Wt. 353.46; <br><br> JV-cvanomettivl-2JV-biscvclohexvlmethvlmalonamide (Compound 24); 'H NMR(DMSO): 8.34 (t, J=5Hz, IH), 7.93 (t, J=5Hz, IH), 4.09 (d, J=6Hz, 2H), 3.23 (dd, J=7,9Hz, IH), 3.0 (m, IH), 2.8 (m, IH), 1.6 (m, 12H), 1.4 (m, IH), 1.1 (m, 7H), 0.86 (m, 15 4H); MS (m/e) = 334.00, M.Wt. 333.47; <br><br> #-cvanomethvl-2-cvclohexv]methvl-jVW2-methoxvbenzvDma1onamide (Compound 25); 'H NMR(DMSO): 8.44 (t, J=5Hz, IH), 8.27 (t, J=6Hz, IH), 7.24 (dt, J=2,7Hz, IH), 7.10 (dd, J=2,7Hz, IH), 6.96 (d, J=7Hz, IH), 6.88 (dt, J=7,lHz, IH), 4.30 (dd, J=6,16Hz, IH), 4.20 (dd, J=5,16Hz, IH), 4.12 (d, J=6Hz, 2H), 3.79 (s, 3H), 3.3 (m, 20 IH), 1.6 (m, 7H), 1.1 (m, 4H), 0.85 (m, 2H); MS (m/e) = 358.03, M.Wt. 357.45; <br><br> A^-cvanomethvl-2-cvclohexvlmethvl-Ar-C 1 -phenvlethvDmalonamide (Compound 0 26); 'H NMR(DMSO): 8.25 (m, IH), 7.4 (m, 5H), 4.02 (m, 2H), 3.18 (s, 3H), 3.25 (m, <br><br> IH), 1.6 (m, 7H), 1.1 (m, 4H), 0.7 (m, 2H); MS (m/e) = 328.08, M.Wt. 327.42; <br><br> jV-benzvl-JV-cvanomethvl-2-cvclohexvlm.ethvl-A/'-methvlmalonamide (Compound 25 27); 'HNMR(DMSO): 8.62 (m, IH), 7.3 (m, 5H), 4.5 (m, 2H), 4.13 (d,J=6Hz, 2H), 3.7 (m, IH), 2.93 (s, 3H), 1.6 (m, 7H), 1.1 (m, 4H), 0.88 (m, 2H); MS (m/e) = 342.09, M.Wt. 341.45; <br><br> Ar-cvanomethvl-2-cvclohexvlmethvl-j\r-f3-nitrobenzvl'&gt;malonamide (Compound 28); lHNMR(DMSO): 8.6 (t, IH), 8.5 (t, IH), 8.1 (m, 2H), 7.6 (m, 2H), 4.1 (m, 2H), 1.6 30 (m, 7H), 1.1 (m, 4H), 0.8 (m, 2H); MS (m/e) = 373.07, M.Wt. 372.42; <br><br> T/-cvanomethvl-2-cvclohexv1methvl-Ar-f4-methoxvbenzvDmalonamide <br><br> 48 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> (Compound 29); 'H NMR(DMSO): 8.42 (t, J=5Hz, IH), 8.38 (t, J=6Hz, IH), 7.14 (d, J=9Hz, 2H), 6.86 (d, J=9Hz, 2H), 4.25 (dd, J=6,15Hz, IH), 4.15 (dd, J=7,16Hz, IH), 3.71 (s, 3H), 3.27 (t, J=8Hz, IH), 1.6 (m, 7H), 1.1 (m, 4H), 0.84 (m, 2H), 4.11 (d,J=6Hz, 2H); MS (m/e) = 356.97, M.Wt. 357.45; <br><br> 5 N-G-carbamovlphenvlWV-cvanomethvl^-cvclohexvlmethvlmalonamide <br><br> (Compound 30); !HNMR(DMSO): 10.14 (s, IH), 8.48 (t, IH), 8.03 (s, IH), 7.75 (d, IH), 7.54 (d, IH), 7.35 (m, 2H), 4.12 (d, 2H), 3.4 (t, IH), 1.6 (m, 7H), 1.1 (m, 4H), 0.9 (m, 2H), 3.29 (s, 3H); MS (m/e) = 357.11, M.Wt. 356.42; <br><br> Ar-cvanomethvl-2-cvclohexvlmethvl-A^-nvrid-3-vlmethvlmalonamide (Compound 10 31); 'HNMR(DMSO): 8.4 (in, 4H), 7.55 (d, IH), 7.25 (dd, IH), 4.28 (dd, IH), 4.18 (dd, IH), 4.05 (d, 2H), 3.2 (m, IH), 1.6 (m, 7H), 1.01 (m, 4H), 0.78 (m, 2H); MS (m/e) = 329.03, M.Wt. 328.41; <br><br> Ar-(4-carbamovlphenvlV7V,-cvanomethvl-2-cvclohexvlmethvlmalonamide (Compound 32); 'H NMR(DMSO): 10.22 (s, 2H), 8.50 (t, J=6Hz, IH), 7.83 (d, J=9Hz 2H), 15 7.64 (d, J=9Hz, 2H), 7.52 (s, IH), 4.13 (d, J=6Hz, 2H), 3.48 (t, J=7Hz, IH), 1.7 (m, 7H), 1.1 (m, 4H), 0.9 (m, 2H); MS (m/e) = 357.04, M.Wt. 356.42; <br><br> jV-cvanomethvl-2-cvclohexvlmethvl-iV-tetrahvdrofur-2-vlmethvlmalonamide (Compound 33); 'H NMR(DMSO): 8.38 (t, J=5Hz, IH), 7.98 (t, J=4Hz, IH), 4.10 (d, J=6Hz 2H), 3.8 (m, 2H), 3.6 (m, IH), 3.2 (m, 4H), 1.8 (m, 3H), 1.6 (m, 7H), 1.1 (m, 4H), 20 0.85 (m, 2H); MS (m/e) = 322.02, M.Wt. 321.41; <br><br> JV-cvanomethvl-2-cvclohexvImethvl-3 -(3.4-dihvdro-2//-quinolin-1 - vlt-3 -oxopronionamide (Compound 34); 'HNMR(DMSO): 8.5 (m, IH), 7.35 (m, IH), 7.2 (m,. 4H), 4.1 (m, 2H), 3.82 (dd, IH), 2.78 (t, IH), 2.72 (t, IH), 2.59 (m, IH), 1.8 (m, 2H), 1.5 (m, 7H), 1.0 (m, 4H), 0.7 (m, 2H); MS (m/e) = 354.02, M.Wt. 353.46; 25 iy-fert-butvl-Ar-cvanomefovl-2-cvclohexvlmethvl-jV-methvlmalonamide <br><br> (Compound 35); 'H NMR(DMSO): 8.41 (t, J=5Hz, IH), 4.09 (d, J=5Hz, IH), 3.56 (t, J=7Hz, IH), 2.86 (s, 3H), 1.6 (m, 7H), 1.31 (s, 9H), 1.1 (m, 4H), 0.8 (m, 2H); MS (m/e) = 308.04, M.Wt. 307.43; <br><br> A^-cvanomethvl^-cvclohexvlmethvl-A^ -methvl-AP -proavlmalonamide (Compound 30 36); XH NMR(DMSO): 8.5 (m, IH), 4.10 (m, 2HJ, 3.60 (t, J=7Hz, IH), 3.2 (m, 2H), 2.96 (s, 3H), 1.65 (m, 7H), 1.45 (m, 2H), 1.1 (m, 4H), 0.8 (m, 5H); MS (m/e) = 294.02, M.Wt. <br><br> 49 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> 293.40; <br><br> jV-butvl-jV-cvanomethvl-2-cvclohexvlmethvl-iV-methvlmalonamide (Compound 37); !HNMR(DMSO): 8.5 (m, IH), 4.10 (d, J=5Hz, 2H), 3.60 (t, IH), 3.3 (m, 2H), 2.95 (s, 3H), 1.6 (m, 7H), 1.4 (m, 2H), 1.1 (m, 6H), 0.8 (m, 5H); MS (m/e) = 308.01, M.Wt. <br><br> 5 307.43; <br><br> iV-cvanomethvl-2-cvclohexvlmethvl-A^.A^-dimethvlmalonamide (Compound 38); JH NMR(DMSO): 8.55 (t, J=5Hz, IH), 4.11 (d, J=7Hz, 2H), 3.62 (t, J=8Hz, IH), 2.99 (s, 3H), 2.81 (s, 3H), 1.6 (m, 7H), 1.1 (m, 4H), 0.85 (m, 2H); MS (m/e) = 266.01, M.Wt. 265.18; <br><br> 10 W-benzvWV'-cvanomethvl-2-f2-phenvlsulfanvlethvflma1nnamide (Compound 39); <br><br> 'H NMR(DMSO): 8.56 (t, J=6Hz, IH), 8.49 (t, J=6Hz, IH), 7.3 (m, 10H), 4.29 (d, J=6Hz, 2H), 4.14 (d, J=6Hz, 2H), 3.40 (t, J=7Hz, IH), 2.86 (t, J=8Hz, 2H), 2.05 (m, 2H); MS (m/e) = 368.02, M.Wt. 367.14; and <br><br> 2-(2-phenvlsulfonvlethvlViV-benzvl-JV-cvanomethvlmalonamide (Compound 40); 15 'H NMR(DMSO): 8.56 (t, J=6Hz, IH), 8.43 (t, J=6Hz, IH), 7.86 (d, J=7Hz, 2H), 7.79 (t, J=5Hz, IH), 7.68 (t, J=8Hz, 2H), 7.25 (m, 5H), 4.26 (d, J=6Hz, 2H), 4.13 (d, J=6Hz, 2H), 3.36 (m, IH), 3.19 (m, 2H), 2.00 (m, 2H); MS (m/e) = 400.04, M.Wt. 399.47; <br><br> 2-r2-Benzenesulfonvl-ethvlVN-r&lt;rSVl-&lt;'l-benzooxazol-2-vl-me&amp;anovlVpentvll-iV-benzvl-malonamide (Compound 41) 'H NMR(DMSO): 8.56 (d, J=6Hz, IH), 8.2 (m, IH), 20 8.0-7.5 (m, 9H), 7.3-7.1 (m, 5H), 5.3 (m, IH), 4.24 (t, J=6Hz, 2H), 3.41 (t, J=7Hz, IH), 3.18 (m, 2H), 1.96 (m, 3H), 1.67 (m, IH), 1.30 (m, 4H), 0.82 (m, 3H); MS (m/e) = 576.27, M.Wt. 575.21; and <br><br> N. jV-Bis-f CSV 1 -(1 -benzooxazol-2-vl-methanovlVpropvll-2-cvclohexvlmethvl-malonamide rCompound 42) 'H NMR(DMSO): 8.41 (d, J=6Hz, 2H), 8.00 (d, J=8Hz, 2H), 25 7.89 (d, J=8Hz, 2H), 7.65 (t, J=7Hz, 2H), 7.53 (t, J=8Hz, 2H), 5.19 (m, 2H), 3.42 (t, J=8Hz, IH), 1.98 (m, 2H), 1.74 (m, 2H), 1.52 (m, 7H), 0.94 (m, 10H), 0.77 (m, 2H); MS (m/e) = 572.26, M.Wt. 573.4. <br><br> 30 EXAMPLE 6 <br><br> Cathepsin S Assay <br><br> 50 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> Solutions of test compounds in varying concentrations were prepared in 10 p.L of dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 (iL, comprising: MES, 50 mM (pH 6.5); EDTA, 2.5 mM; andNaCl, 100 mM). Human cathepsin S (0.158 pMoles 5 in 25 |xL of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-10 seconds on a shaker plate, covered and incubated for 30 minutes at ambient temperature. Z-Val-Val-Arg-AMC (9 nMoles in 25 jxL of assay buffer) was added to the assay solutions and hydrolysis was followed spectrophotometrically at (A, 460 nm) for 5 minutes. Apparent inhibition constants (Kj) were calculated from the enzyme progress 10 curves using standard mathematical models. <br><br> 15 <br><br> EXAMPLE 7 Cathepsin B Assay <br><br> Solutions of test compounds in varying concentrations were prepared in 10 pL of dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 pL, comprising: Nfl-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 50 mM (pH 6); polyoxyethylenesorbitanmonolaurate, 0.05%; and dithiothreitol (DTT), 2.5 mM). Human 20 cathepsin B (0.025 pMoles in 25 pL of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-10 seconds on a shaker plate, covered and incubated for 30 minutes at ambient temperature. Z-FR-AMC (20 nMoles in 25 jjiL of assay buffer) was added to the assay solutions and hydrolysis was followed spectrophotometrically at (k 460 nm) for 5 minutes. Apparent inhibition constants (Kj) were calculated from the enzyme 25 progress curves using standard mathematical models. 1 <br><br> EXAMPLE 8 Cathepsin K Assay <br><br> 30 <br><br> Solutions of test compounds in varying concentrations were prepared in 10 pL of <br><br> 51 <br><br> WO 02/098406 <br><br> PCT/US02/17922 <br><br> 10 <br><br> dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 (J.L, comprising: MES, 50 mM (pH 5.5); EDTA, 2.5 mM; and DTT, 2.5 mM). Human cathepsin K (0.0906 pMoles in 25 |xL of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-10 seconds on a shaker plate, covered and incubated for 30 minutes at ambient temperature. Z-Phe-Arg-AMC (4 nMoles in 25 p,L of assay buffer) was added to the assay solutions and hydrolysis was followed spectrophotometrically at (X 460 nm) for 5 minutes. Apparent inhibition constants (K,) were calculated from the enzyme progress curves using standard mathematical models. <br><br> EXAMPLE 9 Cathepsin L Assay <br><br> Solutions of test compounds in varying concentrations were prepared in 10 jj,L of 15 dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 \iL, comprising: MES, 50 mM (pH 5.5); EDTA, 2.5 mM; and DTT, 2.5 mM). Human cathepsin L (0.05 pMoles in 25 pL of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-10 seconds on a shaker plate, covered and incubated for 30 minutes at ambient temperature. Z-Phe-Arg-AMC (1 nMoles in 25 jj,L of assay buffer) was added to the assay 20 solutions and hydrolysis was followed spectrophotometrically at (A, 460 nm) for 5 minutes. Apparent inhibition constants (Kj) were calculated from the enzyme progress curves using standard mathematical models. <br><br> Compounds of the invention were tested according to the above-described assays for protease inhibition and observed to exhibit selective cathepsin S inhibitory activity. 25 For example, the compounds of the invention were found to inhibit cathepsin S protease activity at concentrations that are least 50 fold less than those concentrations required to produce an equiactive inhibition of cathepsin K protease activity. The apparent inhibition constants (BQ for compounds of the invention, against Cathepsin S, were in the range from about 10'10M to about 10"7M. <br><br> 30 <br><br> 52 <br><br></p> </div>

Claims (2)

<div class="application article clearfix printTableText" id="claims"> <p lang="en"> WO 02/098406<br><br> PCT/US02/17922<br><br> EXAMPLE 10<br><br> Representative Phannaceutical Formulations Containing a Compound of Formula I<br><br> 5 ORAL FORMULATION<br><br> Compound of Formula I 10-100 mg<br><br> Citric Acid Monohydrate 105 mg<br><br> Sodium Hydroxide 18 mg Flavoring<br><br> 10 Water q.s. to 100 mL<br><br> INTRAVENOUS FORMULATION<br><br> Compound of Formula I 0.1-10 mg<br><br> Dextrose Monohydrate q.s. to make isotonic<br><br> 15 Citric Acid Monohydrate 1.05 mg<br><br> Sodium Hydroxide 0.18 mg<br><br> Water for Injection q.s. to 1.0 mL<br><br> TABLET FORMULATION<br><br> 20 Compound of Formula I 1%<br><br> Macrocrystalline Cellulose 73%<br><br> Stearic Acid 25%<br><br> Colloidal Silica 1%.<br><br> 25<br><br> 53<br><br> WO 02/098406<br><br> PCT/US02/17922<br><br> WE CLAIM:<br><br> 1. A compound of Formula I:<br><br> 10<br><br> R<br><br> R<br><br> x'<br><br> o o<br><br> I<br><br> 5 in which:<br><br> X1 is -NHC(R1)(R2)X2;<br><br> X2 is cyano, -C(R7)(R8)X3; R6 is hydrogen or (Ci-6) alkyl; R7 and R8 together form oxo;<br><br> X3 comprises a heteromonocyclic ring containing 4 to 6 ring member atoms or a fused heterobicyclic ring system containing 8 to 14 ring member atoms and any carbocyclic ketone, iminoketone or thioketone derivative thereof;<br><br> X4 is a bond or (C1.6)alkyl; R12 at each occurrence independently is hydrogen,<br><br> (Ci-6)alkyl and R14 is (C3-io)cycloalkyl(Co-6)alkyl,<br><br> 15<br><br> 20<br><br> 54<br><br> intellectual property 0fice of n.z<br><br> 1 6 JUN 2005 RECEIVED<br><br> WO 02/(198406<br><br> PCT/US02/17922<br><br> hetero(C3.,o)cycloalkyl(Co.3)alkyl, (C6.10)aryl(C0.6)alkyl, hetero(C5.10)aryl(C0.6)alkyl, (C9-io)bicycloaryl(C0.6)alkyl or hetero(C8.10)bicycloaryl(C0.6)alkyl;<br><br> R1 is hydrogen; and R2 is hydrogen,<br><br> R3 is -C(R6)(R6)X5, wherein R6 is as defined above and X5 is selected from 5 -X4R12, -R14, -X4SR14, -X4S(0)2R14, wherein X4, R12 and R14 are as defined above;<br><br> R4 is -NR6R6, -NR6R14, -NR6R15 or -NR6X5C(0)R14 wherein R6, X5 and R14 are as described above and R15 is hydrogen, -(Ci^alkyl;<br><br> intellectual property office of n.z<br><br> 16 JUN 2005 RECEl \/gp<br><br> WO 02/098406 PCT/US02/17922<br><br> 10<br><br> 15<br><br> ^ A<br><br> wherein within R and R any alicyclic or aromatic ring system may be substituted further by nitro, -X4OR12, -X4C(0)NR12R12, -X4Ok14, and within R3 and R4 any aliphatic moiety may be substituted further by cyano; and<br><br> &lt; i •<br><br> the iV-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.<br><br> 20<br><br> 2. The compound of Claim 1 in which:<br><br> 25 X1 is ~NHC(R')(R2)X2 or -NHX3;<br><br> X2 is cyano, -C(0)X3, -C(0)CF3, -C(0)CF2CF2R9, ~CH=CHS(0)2R5, -C(0)CF2C(0)NR5R5, -C(0)C(0)NR5R6, -C(0)C(0)0R5, -C(0)CH20R5, -C(0)CH2N(R6)S02R5 or -C(0)C(0)R5; wherein R5 and R6 are as described above;<br><br> X3 comprises a heteromonocyclic ring containing 4 to 6 ring member atoms or a 30 fused heterobicyclic ring system containing 8 to 14 ring member atoms and any carbocyclic ketone, iminoketone or thioketone derivative thereof;<br><br> 56<br><br> ""''■LLL'U^HHU^HTy OFFICE<br><br> 2 5 M 2005 I - RECPiv/ppf I<br><br> WO 02/098406 PCT/US02/17922<br><br> wherein within Rs, X2 or X5 any alicyclic or aromatic ring system may be substituted further by 1 to 5 radicals independently selected from (C,.6)alkyl or -X40C(0)R12 and/or 1 radical selected from -R14, -X4C(0)R14 or -X40C(0)R14;<br><br> wherein X4, R12 and R14 are as described above;<br><br> 5 R1 is hydrogen or (Cw)alkyl and R2 is hydrogen, -X4OR12,<br><br> (C5.10)heteroaryl(CM)alkyl, (C5.10)aiyl(CM)alkyl, (C5.I0)cycloalkyl(C0.6)alkyl, (Cs.to)heterocycloalkyl(Co_£)alkyl or (Cw)alkyl; or R1 and R2 taken together with the carbon atom to which both R1 and R2 are attached form (C3.8)cycloalkylene or (C3.8)heterocycloalkylene; wherein within said R2 any heteroaryl, aryl, cycloalkyl, 10 heterocycloalkyl, cycloalkylene or heterocycloalkylene is optionally substituted with 1 to 3 radicals independently selected from (C,.s)alkyl and hydroxy;<br><br> R3 is -CH2X5, wherein Xs at each occurrence independently is selected from -X4SR12, -X4C(0)NR12R12, -X4S(0)2R13, -X4C(0)R13, -X4SR14, -R14, -X4S(0)2R14, -X4R12, -X4C(0)R14, -X4C(0)NR14R12, wherein X4, R12, R13 and R14 are as defined above; 15 .R4 is -NR6R6, -NR6R14, -NR6R15 or-NR6X5C(0)R14 wherein R6, X5 and R14 are as described above and R15 is hydrogen, -(C,.6)alkyl or -X5OR6 wherein Xs is as described above; or R6 and R15 together with the nitrogen atom to which R6 and R15 are attached form hetero(C3.,0)cycloalkyl, hetero(Cj_]0)aryl or hetero(Cg.i0)bicycloaryl;<br><br> wherein within R3 and R4 any alicyclic or aromatic ring system may be substituted 20 further by 1-5 radicals independently selected from (C1.s)alkyl, cyano, halo, nitro, halo-substituted(CM)alkyl, -X4OR12, -X4C(0)0R12, -X4C(0)R13, -X4C(0)NRI2R12, -X4NR12S(0)2R12 and/or 1 radical selected from -R14, -X4OR14 and -X4C(0)NR,4R12; within R3 and R4 any aliphatic moiety may be substituted further by 1-5 radicals independently selected from cyano; wherein X4, R12, R13 and R14 are as described above; with the proviso 25 that only one bicyclic ring structure is present within R3 or R4; and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.<br><br> 30<br><br> 3. The compound of Claim 2 in which:<br><br> 57<br><br> WO 02/098406<br><br> PCT/US02/17922<br><br> X1 is -NHCCR^CR^X2 or -NHX3;<br><br> X2 is cyano, -C(0)X3, -CF3, -CF2CF3, (E)-2-benzenesulfonyl-vinyl, 2-dimethylcarbamoyl-2,2-difluoro-acetyl, 1 -benzylcarbamoyl-methanoyl,<br><br>
1-benzyloxy(oxalyl), 2-benzyloxy-acetyl, 2-benzenesulfonylamino-ethanoyl or<br><br> 2-oxo-2-phenyl-ethanoyl;<br><br> X3 is l#-benzoimidazol-2-yl, pyrimidin-2-yl, benzooxazol-2-yl, benzothiazol-2-yl, pyridazin-3-yl, 3-phenyl-[ 1,2,4]oxadiazol-5-yl, 3-ethyl-[l,2,4]oxadiazol-5-yl, 2-methyl-4-oxo-tetrahydro-furan-3-yl, 2-ethyl-4-oxo-tetrahydro-furan-3-yl,.<br><br> 4-oxo-1 -(1 -phenyl-methanoyl)-pyrrolidin-3 -yl or (S)-2-Acetoxy-4-oxo-azetidin-3-yl;<br><br> R1 is hydrogen or methyl and R2 is hydrogen, methoxymethyl, (C^alkyl, phenethyl, thiophen-2-yl or 5-methyl-furan-2-yl, or (ii) R1 and R2 taken together with the carbon atom to which both R1 and R2 are attached form cyclopropylene, tetrahydro-pyran-4-ylene or methyl-piperidin-4-ylene.<br><br> 4. The compound of claim 3 in which R3 is selected from thiophene-2-sulfonylmethyl,<br><br> 3-chloro-2-fluoro-phenyhnethanesulfonylmethyl, benzenesulfonylmethyl, phenylmethanesulfonylmethyl,<br><br> 2-(l,l-difluoro-methoxy)-phenylmethanesulfonylmethyl,2-benzenesulfonyl-ethyl, 2-(pyridine-2-sulfonyl)-ethyl, 2-(pyridine-4-sulfonyl)-ethyL,<br><br> 2-phenyhnethanesuIfonyl-ethyl, oxy-pyridin-2-ylmethanesulfonylmethyl, prop-2-ene-l-sulfonylmethyl, 4-methoxy-phenylmethanesulfonylmethyl, /j-tolylmethanesulfonylmethyl, 4-chloro-phenyhnethanesulfonylmethyl,<br><br> o-tolylmethanesulfonylmethyl, 3,5-dimethyl-phenyhnethanesulfonylmethyl,<br><br> 4-trifluoromethyl-phenyhnethanesulfonylmethyl, 4-trifluoromethoxy-phenylmethanesulfonylmettiyl,<br><br> 2-bromo-phenylmethanesulfonylmethyl, pyridin-2-yhnethanesulfonylmethyl, pyridin-3-ylmethanesulfonyhnethyl, pyridin-4-ylmethanesulfonylme1hyl, naphthalen-2-yhnethanesulfonylmethyl, 3-methyl-phenyhnethanesulfonylmethyl,<br><br> 3-trifluoromethyl-phenylmethanesulfonylmethyl,<br><br> 3-trifluoromethoxy-phenylmethanesulfonylmethyl,<br><br> 4-fluoro-2-trifluoromethoxy-phenyhnethanesulfonylmethyl,<br><br> 58<br><br> WO 02/098406<br><br> PCT/US02/17922<br><br> 2-fluoro-6-trifluoromethyl-phenylmethanesulfonylmethyl,<br><br> 3-chloro-phenyImethanesulfonylmethyl, 2-fluoro-phenylmethanesulfonylmethyl, 2-trifluoro-phenylmethanesulfonylmethyl,2-cyano-pheaylmethanesulfonylmethyl,<br><br> 4-?er/-butyl-phenylmethanesulfonylmethyl,<br><br> 2-fluoro-3-methyl-phenylmethanesulfony3methyl,<br><br> 3-fluoro-phenylmethanesulfonylmethyl,4-fluoro-phenylmethanesulfonylmethyl, 2-chloro-phenyImethanesulfonylmethyl,<br><br> 2.5-difluoro-phenylmethanesulfonylmethyl,<br><br> 2.6-difluoro-phenylmethanesulfonylmethyl, 2,5-dichloro-phenyhnethanesulfonylmethyl,<br><br> 3.4-dichloro-phenylmethanesulfonylmethyl, 2-(l,l-difluoro-methoxy)-phenylmethanesulfonylmethyl, 2-cyano-phenylmethanesulfonylmethyl, 3-cyano-phenylmethanesulfonylmethyl, 2-trifluoromethoxy-phenylmethanesulfonylmethyl,<br><br> 2.3-difluoro-phenylmethanesulfonylmethyl,<br><br> 2.5-difluoro-phenylmethanesulfonylmethyl, biphenyl-2-ylmethanesulfonylmethyl, cyclohexylmethyl, 3-fluoro-phenylmethanesulfonylmethyl,<br><br> 3.4-difluoro-phenylmethanesulfonylmethyl, 2,4-difluoro-phenylmethanesulfonylmeth.yl, 2,4,6-trifluoro-phenylmethanesuIfonylmethyl, 2,4,5-trifluoro-phenyhnethanesulfonylmethyl,<br><br> 2.3.4-trifluoro-phenylmethanesulfonylmethyl,<br><br> 2.3.5-trifluoro-phenylmethanesulfonylmethyl,<br><br> 2.5.6-trifluoro-phenylmethanesulfonylmethyl, 2-chloro-5-trifluoromethylphenyImethanesulfonyImethyl, 2-methyl-propane-l-sulfonyl,<br><br> 2-fluoro-3-trifluoromethylphenylmethanesulfonylmethyl, 2-fluoro-4-trifluoromethylphenylmethanesulfonylmethyl, 2-fluoro-5-trifluoromethylphenylmethanesulfonylmethyl,<br><br> 4-fluoro-3-trifluoromethylphenylmethanesulfonylmethyl, 2-methoxy-phenylmethanesulfonylmethyl, 3,5<br><br> 59<br><br> WO 02/098406<br><br> PCT/US02/17922<br><br> bis-trifluoromethyl-phenyhnethanesulfonylmethyl,<br><br> 4-difluoromethoxy-phenyhnethanesulfonylmethyl,<br><br> 2-difluoromethoxy-phenyhnethanesulfonylmethyl,<br><br> 3-difluoromethoxy-phenylmethanesulfonylmethyl,<br><br> 2,6-dichloro-phenylmethanesulfonyhnethyl,biphenyl-4-yhnethanesulfonylmethyl, 3,5-dimethyl-isoxazol-4-ylmethanesulfonylmethyl,<br><br> 5-chloro-thiophen-2-yImethanesuIfonyImethyI,<br><br> 2-[4-( 1,1 -Difluoro-methoxy)-benzenesulfonyl]-ethyl,<br><br> 2-[2-(l, 1 -Difluoro-methoxy)-benzenesulfonyl]-ethyl, 2-[3-(l,l -DifluoroTmethoxy)-benzenesulfonyl]-ethyl, 2-(4-trifluoromethoxy-benzenesulfonyl)-ethyl, 2-(3-trifluoromethoxy-benzenesulfonyl)-ethyl, 2-(2-trifhioromethoxy-benzenesulfonyl)-ethyl,<br><br> (cyanomethyl-methyl-carbamoyl)-methyl, butyl, bipheayl-3-ylmethyl, 2-oxo-2-pyrrolidin-l -yl-ethyl, 2-benzeuesulfonyl-ethyl, isobutylsulfanylmethyl, 2-phenylsulfanyl-ethyl, cyclohexylmethanesulfonylmethyl,<br><br> 2-cyclohexyl-ethanesulfonyl, benzyl, naphthalen-2-yl, benzylsulfanylmethyl, 2-trifluoromethyl-benzylsulfanylmethyl, 5-bromo-thiophen-2-ylmethyl phenylsulfanyl-ethyl and cyclopropylmethanesulfonylmethyl.<br><br> 5. The compound of claim 4 in which R4 is selected from phenylamino, benzylamino,<br><br> 4-phenoxy-phenylamino, phenethylaxnino, 3-phenyl-propylamino, moipholin-4-yl, cyclohexylamino, naphthalen-l-ylmethyl-amino, pyridin-3-ylamino, 6-methoxy-pyridin-3-ylamino, diisobutylamino, 4-nitro-benzylamino, 2-thiophen-2-yl-ethylamino, 3-phenoxy-phenylamino, cyanomethyl-amino, (pyridin-3-ylmethyl)-amino, 5,6,7,8-tetrahydro-naphthalen-l-ylamino, 2-pyridin-2-yl-ethylamino, 2,3-dihydro-indol-l-yl, 3,4-dihydro-lH-isoquinolin-2-yl, cyclohexylmethyl-amino, 2-methoxy-benzylamino, 1 -phenyl-ethylamino, {jpyridin-4-ylmethyl)-amino, benzyl-methyl-amino, 3-nitro-benzylamino, 4-methoxy-phenylamino, 3-carbamoyl-phenylamino, 4-carbamoyl-phenylamino, (tetrahydro-furan-2-ylmethyl)-amino, 3,4-dihydxo-2H-quinolin-l-yl, dimethylamino, butylmethylamino,<br><br> 60<br><br> WO 02/098406<br><br> PCT/US02/17922<br><br> diisopropylamino, propylmethylamino, l-(benzooxazole-2-carbonyl)-propylamino and isobutylmethylamino.<br><br> 6. The compound of claim 5 selected from the group consisting of: 2-butyl-JV-cyanomethyl-iV-phenyl-malonamide; AT-Cyanomethyl-2-cyclohexylmethyl-iV-phenyl-malonamide; iV-Cyanomethyl-2-cyclohexylmethyl-iV-phenethyl-malonamide; N-Cyanomethyl-2-cyclohexylmethyl-iV-pyridin-4-ylmethyl-xnalonamide; iV-[l-(Benzooxazole-2-carbonyl)-3-phenyl-propyl]-iV-ben2yl-2-cyclohexylmethyl-malonamide; N-Cyanomethyl-iV-cyclohexyl-2-<br><br> cyclohexylmethyl-malonamide: iV-Benzyl-iV-cyanomethyl-2-cyclohexylmethyl-malonaxnide; N-Cyanomethyl-2-cyclohexylmethyl-7V-(4-phenoxy-phenyl)-malonamide; iV-Cyanomethyl-2-cyclohexylmethyl-iV-(3-phenyl-propyl)-malonamide; iV-Cyanomethyl-2-cyclohexylmethyl-3-moipholin-4-yl-3-oxo-propionamide; 7V-Cyanomethyl-2-cyclohexyhnethyl-iVI-naphthalen-l-yhnethyl-malonamide; ALCyanomethyl-2-cyclohexylmethyl-TV-pyridin-3-yl-malonamide; N-Cyanomethyl-2-cyclohexylmethyl-N',N'-dnsobutyl-malonamide; N-<br><br> Cyanomethyl^-cyclohexylmethyl-iV^-diisopropyl-malonamide; N-Cyanomethyl-2-cyclohexylmethyl-A/l-(6-methoxy-pyridin-3-yl)-malonamide; N-Cyanomethyl-2-cyclohexylmethyl-iV-(2-thiophen-2-yl-ethyl)-malonamide; iV-Cyanomethyl-2-cyclohexylmethyl-JV-(3-phenoxy-phenyl)-malonamide; iV-Cyanomethyl-2-cyclohexylmethyl-An-(4-nitro-benzyl)-malonamide; N,iV-Bis-cyanomethyl-2-cyclohexylmethyl-malonamide;//-Cyanomethyl-2-cyclohexylmethyl-7V-(5,6,7,8-tetrahydro-naphthalen-1 -yl)-malonamide; A/-CyanomethyL2-cyclohexylmethyl-iV-(2-pyridin-2-yl-ethyl)-malonamide;iV-Cyanomethyl-2-cyclohexylmethyl-3-(2,3-dihydro-indol-l-yl)-3-oxo-propionamide;iV-Cyanomethyl-2-cyclohexylmethyl-3-(3,4-dihydro-lH-isoquinolin-2-yl)-3-oxo-propionamide; AT-Cyanomethyl-2^V-bis-cyclohexylmethyl-malonamide; iV-Cyanomethyl-2-cyclohexylmethyl-iV-(2-methoxy-benzyl)-malonamide;iV-Cyanomethyl-2-cyclohexylmethyl-iV-(l-phenyl-ethyl)-malonamide; iV-Benzyl-iV-cyanomethyl-2-cyclohexylmethyl-iV-methyl-<br><br> malonamide; iV-Cyanomethyl-2-cyclohexylmethyl-iV-(3-nitro-benzyl)-<br><br> *<br><br> malonamide; JV-Cyanomethyl-2-cyclohexyhnethyl-iV-(4-methoxy-benzyl)-<br><br> 61<br><br> WO 02/098406<br><br> PCT/US02/17922<br><br> malonamide; Ar-(3-Carbamoyl-phenyl)-//'-cyanomethyl-2-cyclohexylmethyl-malonamide; N-Cyanomethyl-2-cyclohexylmethyl-7V-pyridin-3-ylmethyl-malonamide; iV-(4-carbamoylphenyl)-jV -cyanomethyl-2-<br><br> cyclohexylmethylmalonamide; iV-cyanomethyl-2-cyclohexylmethyl-iV-<br><br> 5 tetrahydrofur-2-ylmethylnialonamide;iV-cyanomethyl-2-cyclohexylmethyl-3-(3,4-<br><br> dihydro-27/-quinolin-1 -yl)-3-oxopropionamide; N-tert-butyk/\p-cyanomethyI-2-cyclohexylraethyl-7Vr-methylmalonamide; iV-cyanomethyl-2-cyclohexybnethyl-7f-methyl-iV'-propylmalonamide; Ar-butyl-Ap-cyanomethyl-2-cyclohexylmethyl-iV-methylmalonamide; 7V-cyanomethyl-2-cyclohexylmethyl-7V;(A/'-<br><br> 10 dimethylmalonamide; iN/-benzyl-7V-cyanomethyl-2-(2-<br><br> phenylsulfanylethyl)malonamide; 2-(2-phenylsulfonylethyl)-N-benzyl-iV-cyanomethylmalonamide; 2-(2-benzenesulfonyl-ethyl)-JV-[(S)-1 -(1-benzooxazol-2-yl-methanoyl)-pentyl]-7V-benzyl-malonamide; NJf-bis-[(S)-1 -(1 -benzooxazol-2-yl-methanoyl)-propyl]-2-cyclohexylmethyl-malonamide; and the N-oxide 15 derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the phaimaceutically acceptable salts and solvates of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.<br><br> 20 7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.<br><br> 8. A use of a compound of Claim 1 or a N-oxide derivative or individual isomer or mixture of isomer thereof; or a pharmaceutically acceptable salt or solvate of such 25 compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives,<br><br> individual isomers and mixtures of isomers thereof, in the manufacture of a medicament for treating a disease in an animal in which inhibition of Cathepsin S can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease.<br><br> 30 9. The use as claimed in claim 8, wherein the disease is selected from the group consisting of arthritis, muscular dystrophy, inflammation, tumor invasion,<br><br> 62<br><br> iniellectual^property office]<br><br> 16 JUN 2005 ft EC ElV E D<br><br> WO
02/098406<br><br> PCT/US02/17922<br><br> glimeruloneptritis, malaria, periodontal disease, metochromatic leukodystrophy and other diseases associated with aberrant activity of cystein proteases.<br><br> 10. A process for preparing a compound of Formula I:<br><br> (A) reacting a compound of Formula 2:<br><br> Vy"<br><br> o o<br><br> 2<br><br> with a compound of formula NH2CR'R2X2, in which R1, R2, R3, R4 and X2 are as defined in the Summary of the Invention for Formula I; or<br><br> (B) reacting a compound of Formula 2 with a compound of Formula NH2X\ in which R3, R4 and X3 are as described in the Summary of the Invention for Formula I; and<br><br> (C) optionally converting a compound of Formula I into a pharmaceutically acceptable salt;<br><br> (D) optionally converting a salt form of a compound of Formula I to non-salt form;<br><br> (E) optionally converting an unoxidized form of a compound of Formula I into a pharmaceutically acceptable N-oxide;<br><br> (F) optionally converting an N-oxide form of a compound of Formula I its unoxidized form;<br><br> (G) optionally resolving an individual isomer of a compound of Formula I from a mixture of isomers;<br><br> (H) optionally converting a non-derivatized compound of Formula I into a pharmaceutically prodrug derivative; and<br><br> (I) optionally converting a prodrug derivative of a compound of Formula I to its non-derivatized form.<br><br> 11. A compound as claimed in claim 1 substantially as herein described with reference to any example thereof<br><br> 12. A pharmaceutical composition as claimed in claim 7 substantially as herein described with reference to any example thereof<br><br> 13. A use as claimed in claim 8 substantially as herein described with reference to any example thereof<br><br> 14. A process as claimed in claim 10 substantially as herein described with reference to intellectual property office OF N.Z<br><br> 16 JUN 2005<br><br> any example thereof<br><br> 63<br><br> </p> </div>
NZ529903A 2001-06-04 2002-06-04 Novel substituted 1,3-propadiamides as cathepsin inhibitors NZ529903A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29574401P 2001-06-04 2001-06-04
PCT/US2002/017922 WO2002098406A1 (en) 2001-06-04 2002-06-04 Novel compounds and compositions as cathepsin inhibitors

Publications (1)

Publication Number Publication Date
NZ529903A true NZ529903A (en) 2005-09-30

Family

ID=23139064

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ529903A NZ529903A (en) 2001-06-04 2002-06-04 Novel substituted 1,3-propadiamides as cathepsin inhibitors

Country Status (18)

Country Link
EP (1) EP1399146A4 (en)
JP (1) JP2005500275A (en)
KR (1) KR20040028769A (en)
CN (1) CN1512880A (en)
BR (1) BR0210172A (en)
CA (1) CA2449021A1 (en)
CO (1) CO5540292A2 (en)
EA (1) EA007334B1 (en)
HR (1) HRP20031092A2 (en)
IL (1) IL159135A0 (en)
MX (1) MXPA03011207A (en)
NO (1) NO20035365L (en)
NZ (1) NZ529903A (en)
PL (1) PL368825A1 (en)
RS (1) RS96203A (en)
SG (1) SG143979A1 (en)
WO (1) WO2002098406A1 (en)
ZA (1) ZA200309371B (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2848232B2 (en) * 1993-02-19 1999-01-20 武田薬品工業株式会社 Aldehyde derivatives
PT1021424E (en) * 1996-06-21 2003-06-30 Upjohn Co TIADIAZOLO AMIDES AS MATRIX METALOPROTEINASE INHIBITORS
US6492362B1 (en) * 1999-09-16 2002-12-10 Axys Pharmaceuticals, Inc. Compounds and compositions as cathepsin S inhibitors

Also Published As

Publication number Publication date
CO5540292A2 (en) 2005-07-29
SG143979A1 (en) 2008-07-29
HRP20031092A2 (en) 2004-04-30
EP1399146A1 (en) 2004-03-24
IL159135A0 (en) 2004-05-12
CA2449021A1 (en) 2002-12-12
CN1512880A (en) 2004-07-14
PL368825A1 (en) 2005-04-04
JP2005500275A (en) 2005-01-06
NO20035365L (en) 2004-02-20
MXPA03011207A (en) 2004-02-26
KR20040028769A (en) 2004-04-03
EP1399146A4 (en) 2006-01-18
WO2002098406A1 (en) 2002-12-12
ZA200309371B (en) 2005-05-27
RS96203A (en) 2006-12-15
EA007334B1 (en) 2006-08-25
BR0210172A (en) 2004-06-22
NO20035365D0 (en) 2003-12-02
EA200301315A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
AU774827B2 (en) N-cyanomethyl amides as protease inhibitors
US6492362B1 (en) Compounds and compositions as cathepsin S inhibitors
US20070135386A1 (en) Novel Compounds and Compositions as Cathepsin Inhibitors
RU2493149C2 (en) Substituted methylphenyl ketones suitable for use as pde4 inhibitors
JPH0296552A (en) Substituted aminomethyltetralines and heterocyclic analogues thereof
WO2006016218A1 (en) Aryl or heteroaryl carbonyl derivatives derivatives useful as vanilloid receptor 1 (vr1) antagonists
AU2007320906A1 (en) Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
US7226921B2 (en) Compounds and compositions as cathepsin S inhibitors
NZ529903A (en) Novel substituted 1,3-propadiamides as cathepsin inhibitors
US20070232654A1 (en) Novel Compounds and Compositions as Cathepsin Inhibitors
AU2002312357A1 (en) Novel compounds and compositions as cathepsin inhibitors
EP1452522A2 (en) Novel compounds and compositions as protease inhibitors
MXPA01009241A (en) Novel compounds and compositions as protease inhibitors
TW200534846A (en) Compounds useful for the treatment of diseases

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)